Affinity chromatography production of clinical human IgG products

Through affinity chromatography and the virus inactivation step on the column, the high cost and low purity problems in the production of IgG preparations in plasma are solved, and efficient, fast and high-purity IgG preparations are achieved, reducing production costs and waste.

CN118891279APending Publication Date: 2024-11-01TAKEDA PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380026155.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-07
Filing Date
2023-03-06
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

The existing production methods for plasma IgG preparations have problems of high cost, low stability and high waste, and it is difficult to effectively recover IgG in plasma, resulting in low yield and low purity.

Method used

Using affinity chromatography method, IgG is extracted from plasma products through multiple affinity capture chromatography steps, and multiple IgG-binding resin combinations are used to combine solvent/detergent virus inactivation steps on the column to achieve efficient, rapid and high-purity IgG production. , avoiding the traditional ethanol grading process.

Benefits of technology

High purity (>99%) IgG production was achieved, reducing unit operation, improving yield and purity, reducing production costs, and maintaining the effect of virus inactivation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118891279A_ABST
    Figure CN118891279A_ABST
Patent Text Reader

Abstract

There is provided an affinity chromatography method of preparing an IgG preparation from a starting material containing IgG, the preparation comprising one or more of IgG1, IgG2, IgG3, and IgG4. The method of the invention comprises contacting said IgG-containing starting material with a first chromatography medium comprising a first solid support bound with Protein A, thereby forming a Protein A binding fraction of an IgG subclass having a Protein A binding affinity and forming a first flow through liquid comprising an IgG subclass not bound to Protein A; and contacting the first flow through liquid with a first affinity ligand chromatography medium, the first affinity ligand chromatography medium comprising a second solid support having a first affinity ligand having an IgG binding affinity bound thereto, thereby forming a first affinity ligand-bound IgG subclass and a second flow through fluid comprising an IgG subclass that is not bound to the first affinity ligand-bound IgG subclass.
Need to check novelty before this filing date? Find Prior Art

Description

Background Art

[0001] Immunoglobulin products from human plasma were first used to treat immunodeficiency in 1952. Initially, intramuscular or subcutaneous administration of IgG was the preferred method. However, in order to inject larger amounts of IgG necessary for effective treatment of various diseases, intravenously administrable products with lower concentrations of IgG (50 mg / mL) were developed. Typically, intravenous immunoglobulin (IVIG) contains pooled immunoglobulin G (IgG) immunoglobulins from the plasma of more than a thousand blood donors. Typically containing more than 95% unmodified IgG with intact Fc-dependent effector functions, and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM), IVIG is a sterile, purified IgG product that is primarily used to treat three major categories of medical conditions: 1. Immunodeficiencies with lower antibody levels, such as X-linked agammaglobulinemia, hypogammaglobulinemia (primary immunodeficiency), and acquired immunodeficiency disorders (secondary immunodeficiency); 2. Inflammatory and autoimmune diseases; and 3. Acute infections.

[0002] Many commercial suppliers of IVIG offer a variety of IVIG products. Compared to the old freeze-dried IVIG products that only contain 50 mg / mL of protein in the dissolved state after re-dissolution, the latest developments are ready-to-use sterile liquid preparations of highly purified and concentrated human IgG antibodies of different volumes and concentrations. Since IgG products such as IVIG are made from pooled human plasma, pathogen contamination in donor blood (especially viruses known to cause various diseases in humans) is a serious problem in the production process. Another important consideration for IgG products is their stability during storage, especially as a ready-to-use preparation. Compared with IVIG, subcutaneously administrable immunoglobulin preparations have the advantages of home treatment and fewer side effects.

[0003] In the fourth part of a series of papers published on the preparation and properties of serum and plasma proteins, Cohn et al. (J. Am. Chem. Soc., 1946, 68 (3): 459-475) first described an alcohol fractionation method for plasma proteins (Method 6), which allowed the separation of fractions rich in IgG from human plasma. A few years later, Oncley et al. (J. Am. Chem. Soc., 1949, 71 (2): 541-550) extended the Cohn method by disclosing a method (Method 9) that resulted in the separation of a purer IgG preparation.

[0004] Although these methods have laid the foundation for the entire plasma-derived blood factor industry, they are unable to provide IgG preparations with sufficiently high concentrations for treating a variety of immune-related diseases including Kawasaki syndrome, immune thrombocytopenic purpura and primary immunodeficiency. Therefore, other methods using various techniques such as ion exchange chromatography have been developed to provide higher purity and higher concentration IgG preparations. Hoppe et al. (Munch Med Wochenschr 1967 (34): 1749-1752) and Falksveden (Swedish Patent No. 348942) and Falksveden and Lundblad (Methods of Plasma Protein Fractionation 1980) first used ion exchange chromatography for this purpose.

[0005] Various modern methods use a precipitation step coupled with column chromatography, such as caprylate precipitation (Lebing et al., Vox Sang 2003 (84): 193-201) and Cohn fraction (I+) II+III ethanol precipitation (Tanaka et al., Braz J Med Biol Res 2000 (33) 37-30). Recently, Teschner et al. (Vox Sang, 2007 (92): 42-55) described a method for producing a 10% IVIG product in which a frozen precipitate is first removed from pooled plasma, followed by a modified Cohn-Oncley cold ethanol fractionation, followed by S / D treatment of the intermediate, ion exchange chromatography, nanofiltration, and optionally ultrafiltration / diafiltration.

[0006] Although these IgG separation methods provide purity, safety and yield, the yield of IgG recovered from plasma can still be improved. For example, Teschner et al. reported that their method resulted in a 65% increase in IgG yield (Teschner et al., supra). Although improved over previously used methods, this IgG recovery still represents at least a loss of about one-third of the IgG present in the pooled plasma fractions during the separation process.

[0007] Due to the limited supply of plasma that can be used to make plasma-derived products, separation of several blood proteins from a common starting plasma pool can be achieved by integrating purification into a single framework. For example, IgG is usually enriched by forming Cohn fraction II+III precipitate or Kistler-Nitschmann precipitate A, and its corresponding supernatant is then used to produce alpha-1-antitrypsin and albumin. Similarly, several methods for manufacturing other plasma proteins such as factor H from byproducts formed in the IgG immunoglobulin manufacturing process have been described, including WO 2008 / 113589 and WO 2011 / 011753.

[0008] Therefore, there is a need for improved and more efficient methods for manufacturing therapeutic IgG products.

[0009] Furthermore, there remains a need for methods of producing high concentration IgG preparations suitable for subcutaneous and / or intramuscular administration.

[0010] Most protein purification methods involve some form of chromatography, in which molecules in solution (mobile phase) are separated based on differences in chemical or physical interactions with a solid material (stationary phase). Gel filtration (also known as size exclusion chromatography or SEC) uses a porous resin material to separate molecules based on size (i.e., physical exclusion). In ion exchange chromatography, molecules are separated based on the strength of their overall ionic interactions (i.e., nonspecific interactions) with the solid phase material. Affinity chromatography methods are widely used for protein purification, however, the methods have not been used for large-scale, industrial-scale purification of plasma proteins such as IgG.

[0011] Affinity chromatography (also known as affinity purification) relies on specific binding interactions between molecules. A specific ligand is chemically immobilized or "coupled" to a solid support so that when a complex mixture passes through the column, those molecules with specific binding affinity for the ligand become bound. After the other sample components are washed away, the bound molecules are stripped from the support, thereby purifying them from the original sample.

[0012] A series of affinity ligands that can be used for producing and purifying proteins are known in the art. Protein A and protein G are the most commonly used capture proteins in human antibody purification. However, protein A and protein G have several disadvantages, including their high cost, low stability and the possibility of contaminating the product by hydrolysis and release of peptide fragments. Usually, protein A and / or protein G derivative affinity resins cannot effectively bind all IgG subclasses of human IgG fractions. Therefore, a kind of effective, preferably compact method is needed, which allows the combination of a wider range of human IgG subclasses by combining protein A or protein G derivative resins with one or more IgG binding resins based on the complementary binding principle.

[0013] The present invention meets these and other needs by providing an efficient, effective chromatography method for the production of IgG that, in one embodiment, avoids the rigorous, time-consuming ethanol fractionation process that is currently standard in the field of plasma products. Summary of the invention

[0014] There remains a need for more efficient, rapid and high yield methods for purifying IgG from feedstock. Since individual IgG isotypes are characterized by different affinities for their conjugated epitopes, methods that allow easy capture and / or purification of one or more isotypes would allow the affinity of a particular isotype to be enhanced and utilized in therapeutic IgG preparations. The present invention provides these and other advantages by providing a novel method for performing IgG-specific affinity chromatography on feedstock containing one or more IgG isotypes.

[0015] Quite unexpectedly, the inventors have discovered that by performing two or more affinity capture chromatography steps on a plasma product starting material, such as a frozen supernatant, a high purity (e.g., >80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99%) IgG product having an IgG subtype profile that is nearly identical to the plasma IgG subtype distribution can be produced in a rapid, efficient and high yield manner. Thus, the present invention provides a method for producing an IgG preparation having an IgG subtype profile, an impurity profile, and combinations thereof that are substantially identical to currently approved commercially available IgG preparations, without resorting to classical plasma fractionation techniques (e.g., Cohn fractionation). This unexpected discovery represents a major advance in the field of separating IgG fractions from large amounts of plasma.

[0016] In an exemplary embodiment, an IgG aqueous solution is provided, which comprises at least about 99.5% IgG and less than about 0.5% impurities, wherein the IgG aqueous solution comprises less than about 0.0025E / mg total IgG, preferably less than about 0.0020E / mg total IgG, more preferably less than about 0.0015E / mg total IgG, and most preferably less than about 0.0012E / mg total IgG active factor XI as an impurity. In another exemplary embodiment, an IgG aqueous solution is provided, which comprises at least about 99.5% IgG and less than about 0.5% impurities, wherein the IgG aqueous solution comprises less than about 3.5μg / mg total IgG, preferably less than about 3.0μg / mg total IgG, more preferably less than about 2.5μg / mg total IgG, and most preferably less than about 2.2μg / mg total IgG level of complement C3 as an impurity. In an exemplary embodiment, an IgG aqueous solution is provided, comprising at least about 99.5% IgG and less than about 0.5% impurities, wherein the IgG aqueous solution comprises complement C3 and factor XI as impurities, wherein complement C3 is present at a level of less than about 3.5 μg / mg total IgG, preferably less than about 3.0 μg / mg total IgG, more preferably less than about 2.5 μg / mg total IgG, most preferably less than about 2.2 μg / mg total IgG, and wherein factor XI is contained at an activity of less than about 0.0025E / mg total IgG, preferably less than about 0.0020E / mg total IgG, more preferably less than about 0.0015E / mg total IgG, and most preferably less than about 0.0012E / mg total IgG. In an exemplary embodiment, an IgG aqueous solution is provided, comprising at least about 99.5% IgG and less than about 0.5% impurities, wherein complement C3 is present at a level of less than about 2.5 μg / mg total IgG, and wherein factor XI is present at an activity of less than about 0.0015E / mg total IgG.

[0017] One embodiment of the present invention relates to an affinity chromatography method, the method preparing an IgG preparation from a starting material containing IgG, the preparation comprising any combination of one or more of IgG1, IgG2, IgG3 and IgG4. In an exemplary embodiment, the method provides an IgG preparation having a predetermined IgG subtype pattern / ratio, a predetermined impurity pattern and a combination thereof. In an exemplary embodiment, the pattern / ratio is substantially consistent with the pattern / ratio of the plasma IgG subtype distribution.

[0018] Surprisingly and unexpectedly, the second column, the column following the Protein A column, binds most of the IgG subtypes that were not bound to the Protein A column. In an exemplary embodiment, the medium on the second column is an antibody. Exemplary antibodies include those that are capable of binding to a common region of one or more IgG subclasses. The antibody can be a full-length monoclonal antibody or an antibody fragment (e.g., Fab, Fab2, single chain, camelid antibody fragment or peptide). In an exemplary embodiment, the column is a CaptureSelect TM CH1-XL affinity matrix (ThermoFisher), or a column with similar IgG binding selectivity.

[0019] Another unexpected result of the present invention is that the inventors have found that the on-column solvent / detergent virus inactivation (SD-VI) step can be performed on the protein material bound to the column without adversely affecting the fidelity of the separation aspect of the process. By incorporating the SD-VI step directly into an established unit operation, rather than performing it as an independent step on the material separated from the chromatographic medium, the discovery further enhances the effectiveness and compactness of the process of the present invention, especially relative to standard fractionation procedures in the art. In fact, more unexpectedly, the purity of the IgG preparation is improved when the on-column SD-VI step is incorporated into the purification because the step is not expected to produce effects other than viral inactivation. The SD-VI step consumes or removes impurities other than viral-derived impurities.

[0020] In an exemplary embodiment, the SD_VI step depletes or removes at least one or more of albumin, apolipoprotein AI, complement C3, haptoglobin, fibrinogen, complement C4-B, complement C1s subcomponent, complement C1r subcomponent, apolipoprotein B-100, alpha-2-macroglobulin. In an exemplary embodiment, these impurities are present in the wash solution from the SD_VI step.

[0021] In various embodiments, the SD_VI step is performed after the IQEQ step of capturing the target therapeutic protein (eg, IgG) on the chromatography medium and producing the flow-through, and before eluting the target therapeutic protein from the chromatography medium.

[0022] The exemplary methods of the present invention can be performed sequentially or as a single unit operation using an array of two or more different IgG binding affinity resins (tandem array) or on a sliding device that allows fully automated continuous chromatography. The principle is not limited to IgG, but can also be used to purify other proteins, such as plasma proteins, such as albumin, A1PI, FVIII, etc.

[0023] The exemplary embodiments of the invention described herein provide the following advantages: compared with the method of using a single protein A or protein G derivatization purification, or another IgG binding affinity purification, it is superior to purify immunoglobulins such as human IgG fractions from raw materials such as plasma and / or plasma fractions (e.g., frozen precipitate supernatants) having a wide range of IgG subclass compositions. The higher purity of the IgG subclass composition obtained is conducive to significantly reducing unit operations so that the purified IgG product is finally made into an administrable drug.

[0024] An exemplary method comprises (a) contacting a starting material containing IgG with a first chromatography medium comprising a first solid support to which protein A is bound, thereby forming a protein A-bound fraction of IgG subclasses having binding affinity to protein A and forming a first flow-through comprising IgG subclasses not bound to protein A; (b) contacting the first flow-through with a first affinity ligand chromatography medium comprising a second solid support having bound thereto a first affinity ligand having binding affinity to IgG, thereby forming (c) eluting the protein A-bound fraction from the first chromatographic medium to form a first eluate and contacting the first eluate with the first affinity ligand chromatographic medium to form a second affinity ligand-bound IgG subclass, and a second flow-through; and (d) eluting a member selected from the first affinity ligand-bound IgG subclass, the second affinity ligand-bound IgG subclass, and a combination thereof from the first affinity ligand column to form a second eluate.

[0025] Exemplary affinity ligand chromatography media include VHH antibody fragments.

[0026] In an exemplary embodiment, the method further comprises (e) combining the first flow-through and the second eluate on the first affinity ligand chromatography medium.

[0027] In an exemplary embodiment, the method includes (f) contacting the second eluate of (d) with a second affinity ligand chromatography medium, the second affinity ligand chromatography medium comprising a third solid support having a second affinity ligand having affinity for IgG bound thereto, thereby forming a third affinity ligand-bound IgG subclass and a second flow-through comprising a fourth IgG subclass that is not bound to the second affinity ligand chromatography medium; and (g) eluting a member selected from the second affinity ligand-bound IgG subclass, the fourth IgG subclass, and a combination thereof from the second affinity ligand chromatography medium, thereby forming a third eluate.

[0028] In an exemplary embodiment, the method includes (h) prior to (g), combining the first flow-through and the second eluate on a second affinity ligand chromatography medium.

[0029] In various embodiments, the method includes (i) prior to (b), contacting the first chromatography medium with a buffer / detergent mixture that does not elute the Protein A bound fraction of the IgG subclass having Protein A binding affinity from the first chromatography medium.

[0030] In some embodiments, the method includes (j) prior to (g), contacting the second affinity ligand chromatography medium with a buffer / detergent mixture that does not elute the second affinity ligand-bound IgG subclass from the second affinity ligand chromatography medium.

[0031] An exemplary aspect of the present invention relates to an affinity chromatography method for preparing an IgG preparation enriched in a first IgG subclass with low protein A binding affinity from a plasma-derived IgG solution lacking protein A binding IgG subclasses. The method comprises (a) contacting the IgG solution lacking protein A binding IgG subclasses with a first affinity ligand chromatography medium, the medium comprising a first solid support having a first affinity ligand with IgG binding affinity bound thereto, thereby forming a first bound fraction and a first flow-through of the first IgG subclass with low protein A binding affinity; and (b) eluting the first bound fraction of the first IgG subclass with low protein A binding affinity, thereby forming a first eluate containing an IgG preparation enriched in the first IgG subclass with low protein A binding.

[0032] In an exemplary embodiment, the method further comprises (c) contacting the first bound fraction of the first IgG subclass with low Protein A binding affinity with a buffer / detergent solution prior to (b), and subsequently removing the detergent solution from the first affinity ligand chromatography medium.

[0033] In an exemplary embodiment, the method further includes (d) after (b), contacting the first eluate with a second chromatographic medium, the second chromatographic medium comprising a solid support having an affinity ligand bound thereto, the ligand having affinity for a second IgG subclass with low protein A binding affinity, thereby forming a first bound fraction of the second IgG subclass with low protein A binding affinity; and (e) eluting the first bound fraction of the second IgG subclass with low protein A binding affinity from the second chromatographic medium, thereby forming a second eluate.

[0034] In some embodiments, the method further comprises (f) contacting the first bound fraction of the second IgG subclass with low Protein A binding affinity with a buffer / detergent solution prior to (e), and subsequently removing the detergent solution from the first chromatography medium.

[0035] In various embodiments, the method further comprises (g) prior to (a), contacting the plasma-derived IgG solution with a protein A chromatography medium comprising protein A bound to a solid support, thereby forming a protein A-bound fraction of IgG subclasses having a high affinity for protein A, and an IgG preparation enriched in a first IgG subclass having a low protein A binding affinity.

[0036] In an exemplary embodiment, the method further comprises (h) eluting the Protein A-bound fraction of the IgG subclass having a high affinity for Protein A from the Protein A chromatography medium, thereby forming a third eluate.

[0037] Exemplary methods include the step of combining two or more of the first eluate, the second eluate, and the third eluate.

[0038] Other aspects and advantages of the invention will be apparent from the following detailed description, drawings, and claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 UV profile of Protein A binding to IgG subclass tandem column I (Protein A and CH1-XL).

[0040] Figure 2 UV profile of non-Protein A binding subclasses on IgG Capture Select resin - superimposed flowthrough (FT).

[0041] Figure 3 UV profile of non-Protein A binding subclasses on IgG Capture Select resin with elution peaks superimposed.

[0042] Figure 4 This is the chromatogram of IGC02.

[0043] Figure 5 This is the chromatogram of IGC01S.

[0044] Figure 6 This is the chromatogram of IGC04.

[0045] Figure 7SDS page silver staining profile for IGC04 silver staining. 1. Loading, frozen supernatant, 1:560 dilution. 2. Flow through, 1:500 dilution. 3. WSD, on-column SD_VI, 1:10 dilution. 4. Wash 2, 1:5 dilution. 5. Wash 3, 1:5 dilution. 6. Eluate, 1:100 dilution. 7. Eluate, 1:50 dilution. 8. Stripping, 1:10 dilution. NuPAGE 4-12% Bis-Tris Midi Gel 1.0mm. 20 wells Cat. No. WG1402BX10, non-reducing SDS running buffer LDS-SB:NP0007, add 50μl sample to 20μl iodoacetamide, incubate at +18 to 26°C for 30 minutes, +50μl buffer LDS-SB:NP0007 at 70°C for 10 minutes. Lanes 8 and 9 show that the purity level of the eluate is unexpectedly high.

[0046] Figure 8 The chromatogram of IGC06. Conductivity (red): UV280 (blue) UV254 (purple) pH: green.

[0047] Fig. 9 SDS page silver stain profile for IGC06 silver stain. 1. Molecular weight marker. 2. Blank 3. Load, frozen supernatant, 1:560 dilution. 4. Flow through, 1:500 dilution. 5. WSD, on-column SD_VI, 1:10 dilution. 6. Wash 2, 1:5 dilution. 7. Wash 3, 1:5 dilution. 8. Elution, 1:100 dilution IgG fraction. 9. Elution, 1:50 dilution IgG fraction. 10. Stripping, 1:10 dilution. NuPAGE 4-12% Bis-Tris Midi Gel 1.0mm. 20 wells Cat. No. WG1402BX10. Non-reducing SDS running buffer LDS-SB: NP0007. Add 50μl sample to 20μl iodoacetamide and incubate at +18 to 26°C for 30 minutes. +50 μl buffer LDS-SB:NP0007 and incubate at 70°C for 10 min.

[0048] Fig.10 A model flow diagram for loading the test material (10% polyclonal immunoglobulin) onto a protein A column.

[0049] Fig.11 To display from Fig.10 A model flow diagram for equally splitting the eluate from a chromatography column into separate columns, each containing a separate affinity chromatography medium. The eluate from each of these columns is collected separately.

[0050] Fig.12Figure 1 is a model flow diagram showing the test material (frozen supernatant) loaded onto a column of Protein A. The eluate from this column is loaded onto a column of affinity chromatography media (e.g., Capture Select CH1-XL).

[0051] Fig.13 is a model flow diagram showing the eluate from a Protein A chromatography of frozen supernatant loaded onto an exemplary affinity ligand chromatography medium (CH1-XL).

[0052] Fig.14 A model flow diagram showing frozen supernatant loaded onto a tandem array of Protein A and affinity chromatography media. After loading the frozen supernatant, a wash step is performed on the array. The eluate contains a wide range of IgG subclasses.

[0053] Fig.15 Model flow diagram of a three-column array (TRIDEM) of Protein A, Capture Select CH1-XL and Capture Select IgG3. The cryoprecipitate is loaded onto the array and a wash step is performed. The eluate contains a wide range of IgG subclasses.

[0054] Fig.16 An overview of exemplary tandem and triplet chromatography arrays. DETAILED DESCRIPTION

[0055] A. Introduction

[0056] Provided herein are exemplary embodiments of purifying one or more IgG isotypes from a raw material using a process incorporating at least one affinity ligand-based affinity chromatography method. Exemplary IgG preparations of the invention are prepared from IgG-containing starting materials, such as frozen precipitate supernatants, and provide IgG preparations containing purified immunoglobulins.

[0057] An exemplary method comprises (a) contacting a starting material containing IgG with a first chromatography medium comprising a first solid support to which protein A is bound, thereby forming a protein A-bound fraction of IgG subclasses having binding affinity for protein A and forming a first flow-through comprising IgG subclasses not bound to protein A; (b) contacting the first flow-through with a first affinity ligand chromatography medium comprising a second solid support having bound thereto a first affinity ligand having binding affinity for a selected immunoglobulin. (c) eluting the protein A-bound fraction from the first chromatographic medium to form a first eluate and contacting the first eluate with the first affinity ligand chromatographic medium to form a second affinity ligand-bound IgG subclass, and a second flow-through; and (d) eluting a member selected from the first affinity ligand-bound IgG subclass, the second affinity ligand-bound IgG subclass, and a combination thereof from the first affinity ligand column to form a second eluate.

[0058] Chromatographic media based on protein A cannot bind IgG of all subclasses with similar efficiency. In an exemplary embodiment, the present invention provides methods and systems for separating and / or purifying IgG fractions and IgG subtypes from plasma starting materials using affinity resins based on affinity ligands. Exemplary resins for the present invention include resins recently developed for antibody fusion protein purification. Those resins bind IgG at different sites (patterns), so they can be used to supplement and enhance the use of protein A resins, or overcome the shortcomings of resins based on protein A.

[0059] Furthermore, the affinity chromatography-based methods of the present invention can be programmed in a continuous or semi-continuous mode to achieve high throughput.

[0060] Exemplary embodiments include dedicated wash steps and on-column solvent / detergent, virus inactivation steps ("on-column" SD_VI treatment), thereby reducing the total number of unit operations compared to traditional IgG fractionation and purification. The on-column SD_VI step can be performed on any column or more than one column in the array.

[0061] An exemplary method of the invention comprises at least two viral inactivation / elimination steps (eg, dedicated SD_VI, acidic holding step, nanofiltration 35 nm).

[0062] In various embodiments, the present invention also provides IgG preparations produced using the methods and / or systems of the present invention.

[0063] B. Definition

[0064] Although the terms used herein are considered to be well known to those of ordinary skill in the art, definitions are set forth herein to aid in explaining the subject matter disclosed herein.

[0065] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the subject matter disclosed herein belongs. Although methods, devices and materials similar or equivalent to those described herein can be used in the practice or testing of the subject matter disclosed herein, representative methods, devices and materials are described herein.

[0066] When used in this application, including the claims, the terms "a / an" and "the" mean "one or more". When used with the term "comprising" in the claims and / or specification, the use of the word "a / an" may mean "one", but it is also consistent with the meaning of "one or more", "at least one", and "one or more than one".

[0067] All references to singular features or limitations of the present disclosure shall include the corresponding plural features or limitations and vice versa, unless otherwise stated or clearly implied to the contrary by the context in which the reference is made.

[0068] All combinations of method or process steps as used herein can be performed in any order unless otherwise specified or clearly implied to the contrary by the context in which the recited combination is produced.

[0069] The methods and apparatus of the present disclosure, including components thereof, may include, consist of, or consist essentially of the basic elements and limitations of the embodiments described herein, as well as any additional or optional components or limitations described herein or otherwise useful.

[0070] Unless otherwise indicated, all numbers expressing physical dimensions, quantities of ingredients, properties such as reaction conditions, and the like used in the specification and claims are to be understood as being qualified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and claims are approximations that may vary depending upon the desired properties sought to be obtained by the presently disclosed subject matter.

[0071] As used herein, ranges can be expressed as from "about" one particular value, and / or to "about" another particular value. It is also understood that there are many values ​​disclosed herein, and that each value is also disclosed herein as "about" that particular value in addition to the value itself. For example, if the value "10" is disclosed, then "about 10" is also disclosed. It is also understood that every unit between two particular units is also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

[0072] For the sake of clarity, not all conventional features of the implementations described herein are shown and described. It will be appreciated that in the development of any such actual implementation, many implementation-specific decisions are made to achieve the developer's specific goals, such as complying with application-related restrictions and business-related restrictions, and these specific goals will vary between implementations and between developers. In addition, it will be appreciated that this development work may be complex and time-consuming, but it is still a routine task of engineering design for those of ordinary skill in the art who benefit from the present disclosure.

[0073] Without departing from the spirit and scope of the exemplary embodiments, many modifications and variations can be made to the exemplary embodiments set forth in this disclosure, which will be apparent to those skilled in the art. The specific exemplary embodiments described herein are provided by way of example only, and the disclosure is limited only by the terms of the appended claims and the full scope of equivalents to which such claims are entitled.

[0074] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those of ordinary skill in the art (e.g., in cell culture, molecular genetics, nucleic acid chemistry, hybridization techniques and biochemistry). Standard techniques are used for molecular, genetic and biochemical methods (see generally Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY and Ausubel et al. Short Protocols in Molecular Biology (1999) 4th edition, John Wiley & Sons, Inc., which are incorporated herein by reference) and chemical methods. In addition, for standard immunological techniques, reference is made to Harlow and Lane, A Laboratory Manual Cold Spring Harbor, NY.

[0075] As used herein, the term "IgG-containing starting material" includes plasma, non-frozen plasma, fractions (e.g., Cohn fractions) used in plasma fractionation processes, and recombinant IgG preparations, as well as other sources of raw materials including one or more IgGs for the disclosed processes. In some embodiments, the term refers to a starting material containing human IgG, but the present invention is not limited to the use of starting materials containing human-derived IgG.

[0076] As used herein, the term "low Protein A binding affinity" refers to an Ig species that does not bind to or is easily washed off a chromatographic medium comprising immobilized Protein A. Exemplary species with low Protein A binding affinity are species in which the bound fraction is substantially completely eluted from the Protein A column at a pH above 5, the eluent has a conductivity greater than about 5 mS / cm, or a combination thereof.

[0077] As used herein, "antibody" refers to a polypeptide substantially encoded by one or more immunoglobulin genes or fragments thereof, which specifically binds and recognizes an analyte (antigen). It is recognized that immunoglobulin genes include kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as numerous immunoglobulin variable region genes. Light chains are classified as kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes IgG, IgM, IgA, IgD, and IgE, respectively.

[0078] An exemplary immunoglobulin (antibody) structural unit consists of two pairs of polypeptide chains, each pair having one "light chain" (about 25 kD) and one "heavy chain" (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids that is primarily responsible for antigen recognition. The term variable light chain (V L ) and variable heavy chain (V H ) refer to these light and heavy chains, respectively.

[0079] The terms "antibody" and "immunoglobulin" are used interchangeably and refer in some embodiments to proteins comprising at least two heavy chains (H) and two light chains (L) interconnected by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region (abbreviated herein as CH). In some antibodies, such as naturally occurring IgG antibodies, the heavy chain constant region consists of a hinge and three domains, CHL, CH2, and CH3. In some antibodies, such as naturally occurring IgG antibodies, each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region consists of one domain (abbreviated herein as CL). The VH region and the VL region can be further subdivided into hypervariable regions called complementarity determining regions (CDRs), which are interspersed with more conservative regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs, arranged in the following order from amino terminus to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The heavy chain may or may not have a C-terminal lysine. The term "antibody" may include bispecific antibodies or multispecific antibodies. Exemplary affinity ligands are antibodies or fragments thereof.

[0080] Exemplary antibodies (immunoglobulins) include human IgA, IgD, IgG, IgE or IgM. The antibodies may be IgG1, IgG2, IgG3 and IgG4 antibodies. In some embodiments, as used herein, "IgG" has the structure of a naturally occurring IgG antibody, i.e., it has the same number of heavy chains and light chains and disulfide bonds as a naturally occurring IgG antibody of the same subclass. For example, an IgG antibody may be composed of two heavy chains (HC) and two light chains (LC), wherein the two HCs and LCs are connected by disulfide bridges of the same number and position that occur in naturally occurring Ig antibodies (unless the antibody has been mutated to modify the disulfide bridges).

[0081] Immunoglobulins can be from any commonly known isotype, including but not limited to IgA, secretory IgA, IgG, and IgM. IgG isotypes are divided into subclasses in certain species: IgG1, IgG2, IgG3, and IgG4 in humans, and IgG1, IgG2a, IgG2b, and IgG3 in mice. Immunoglobulins, such as IgG1, exist in several allotypes, which differ from each other in at most a few amino acids. "Antibodies" include, for example, naturally occurring and non-naturally occurring antibodies; monoclonal and polyclonal antibodies; chimeric and humanized antibodies; human and non-human antibodies and fully synthetic antibodies.

[0082] Camelid antibodies are sometimes used in affinity purification procedures. A large portion of camelid antibodies are single domain antibodies, which interact with their antigens through a single heavy chain binding domain without a light chain. The domain is also referred to as "VHH" or "VHH antibody" or "VHH domain". Recombinant VHH antibodies present a complete antigen binding domain of minimal size. The absence of a VL domain allows VHH antibodies to obtain a higher structural flexibility than the VH domain associated with the VL domain. In addition, the complementary determining regions (CDRs) of VHH, especially CDR3, are statistically longer than conventional VH-VL antibodies (Muyldermans S., J. Biotechnol., 2001, 74, 277-302).

[0083] An exemplary affinity ligand is a VHH ligand. A "VHH ligand" refers to a single domain heavy chain antibody or antibody fragment derived from a camelid. In general, a VHH ligand has heavy chains derived from an immunoglobulin naturally lacking light chains, linked together to form a multivalent single polypeptide that retains the antigen binding affinity of the parent intact immunoglobulin, but is much smaller in size and therefore less immunogenic. VHH ligands are described in detail in, e.g., Frenken et al., J. Biotechnol. 78: 11-21 (2000); van der Linden et al., Biochem Biophys. Acta. 1431: 37-46 (1999); Spinelli et al., Biochemistry 39: 1217-1222 (2000); U.S. Patent Application Publication Nos. 20030078402; 2004 / 0142432 and U.S. Patent Nos. 6,399,763 and 6,670,453.

[0084] Exemplary VHH antibodies (and fragments) for use as chromatographic affinity ligands in the methods of the invention include those having affinity for at least one IgG isotype. Exemplary VHH antibodies for use in the methods of the invention are selective for at least a first IgG isotype over a second IgG isotype.

[0085] The term "antigen-binding portion" of an antibody, fragment thereof (or affinity ligand, as used herein) refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed by the term "antigen-binding portion" of an antibody include: (i) a Fab fragment (fragment derived from papain cleavage) or a similar monovalent fragment consisting of the VL, VH, LC, and CH1 domains; (ii) a F(ab')2 fragment (fragment derived from pepsin cleavage) or a similar bivalent fragment comprising two Fab fragments connected by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546) consisting of the VH domain; (vi) isolated complementarity determining regions (CDRs); and (vii) a combination of two or more isolated CDRs, which may optionally be connected by a synthetic linker. In addition, although the two domains VL and VH of the Fv fragment are encoded by different genes, they can be connected by synthetic linkers using recombinant methods, which enable them to be made into a single protein chain, in which the VL region and the VH region are paired to form a monovalent molecule (called single-chain Fv (scFv); see, for example, Bird et al. (1988) Science 242: 423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85: 5879-5883). Such single-chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody. These antibody fragments can be obtained using conventional techniques known to those skilled in the art, and the fragments can be screened for utility in the same manner as intact antibodies. Antigen-binding fragments can be produced by recombinant DNA technology or by enzymatic or chemical cleavage of antibodies.

[0086] As used herein, the term "ultrafiltration (UF)" encompasses a variety of membrane filtration methods in which hydrostatic pressure forces a liquid against a semipermeable membrane. Suspended solids and high molecular weight solutes are retained, while water and low molecular weight solutes pass through the membrane. The separation process is often used to purify and concentrate large molecules (10 3 -10 6 Ultrafiltration is a process for separating colloids such as proteins from small molecules such as sugars and salts.

[0087] As used herein, the term "diafiltration" is performed using the same membrane as ultrafiltration and is a tangential flow filtration. During diafiltration, a buffer is introduced into a circulation tank while the filtrate is removed from the unit operation. During the process where the product is in the retentate (e.g., IgG), diafiltration flushes components from the product pool into the filtrate, thereby exchanging the buffer and reducing the concentration of unwanted substances.

[0088] The term "chromatography" refers to a technique for separating a protein of interest (e.g., an antibody) from other molecules present in a mixture (e.g., contaminants). Typically, the protein of interest is separated from other molecules (e.g., contaminants) due to the different rates at which the individual molecules of the mixture migrate through a stationary medium under the influence of a mobile phase, or during binding and elution. The terms "matrix" or "chromatographic matrix" are used interchangeably herein and refer to any type of adsorbent, resin, or solid phase that separates a protein of interest (e.g., a protein containing an Fc region, such as an immunoglobulin) from other molecules present in a mixture during a separation process. Non-limiting examples include granular, monolithic, or fibrous resins and membranes that can be placed in a column or cartridge. Examples of materials that form matrices include polysaccharides (e.g., agarose and cellulose); and other mechanically stable matrices such as silica (e.g., controlled pore glass), poly(styrenedivinyl) benzene, polyacrylamide, ceramic particles, and derivatives of any of the above substances. Examples of typical matrix types suitable for use in the methods of the present disclosure are cation exchange resins, affinity resins, anion exchange resins, or mixed mode resins. "Ligand" is a functional group that is attached to a chromatographic matrix and determines the binding properties of the matrix. Examples of "ligands" include, but are not limited to, ion exchange groups, hydrophobic interaction groups, hydrophilic interaction groups, sulfophilic interaction groups, metal affinity groups, affinity ligands, bioaffinity groups, and mixed mode groups (combinations of the above). Some preferred ligands that can be used herein include, but are not limited to, strong cation exchange groups such as sulfopropyl, sulfonic acid; strong anion exchange groups such as trimethylammonium chloride; weak cation exchange groups such as carboxylic acids; weak anion exchange groups such as N5N diethylamino or DEAE; hydrophobic interaction groups such as phenyl, butyl, propyl, hexyl; and affinity ligands such as protein A, protein G, and protein L.

[0089] The term "affinity chromatography" refers to a protein separation technique in which a protein of interest (e.g., a protein or antibody containing an Fc region of interest) is specifically bound to a ligand that is specific to the protein of interest. This ligand is generally referred to as an affinity ligand or a biospecific ligand. In some embodiments, an affinity ligand (e.g., protein A or its functional variant) is covalently linked to a chromatographic matrix material, and when a solution contacts the chromatographic matrix, it can be approached by the protein of interest in a dissolved state. The protein of interest usually retains its specific binding affinity to the affinity ligand during the chromatographic step, while other solutes and / or proteins in the mixture will not be significantly or specifically bound to the ligand. The binding of the protein of interest to the immobilized ligand allows contaminating proteins or protein impurities to pass through the chromatographic matrix, while the protein of interest is still specifically bound to the immobilized ligand on the solid phase material. Then under suitable conditions (e.g., low pH, high pH, ​​high salt, competitive ligand, etc.), the protein of interest that is specifically bound is removed in an active form from the immobilized ligand, and it is passed through the chromatographic column together with the elution buffer, without the contaminating proteins or protein impurities that were previously allowed to pass through the column. Any component can be used as a ligand for purifying its respective specific binding protein, such as an antibody. However, in various methods according to the present disclosure, protein A, G, A / G and / or L are used as ligands for target proteins containing Fc regions. One of ordinary skill in the art can easily determine the conditions for eluting a target protein (e.g., a protein containing an Fc region) from an affinity ligand (e.g., protein A). In some embodiments, protein G or protein L or a functional variant thereof can be used as a biospecific ligand. In some embodiments, a biospecific ligand such as protein A is used to bind to a protein containing an Fc region in a pH range of 5-9, washing or rebalancing the biospecific ligand / target protein conjugate, followed by elution with a buffer having a pH of about or less than 4 and containing at least one salt.

[0090] The term "affinity ligand" refers to a ligand capable of capturing one or more IgG species. Exemplary affinity ligands are selected from one IgG species in a mixture of species, and a method is provided by using a column, filter or other medium containing the affinity ligand, by which one or more IgG species can be purified from a mixture containing one or more IgG species. Exemplary affinity ligands are VHH antibodies or fragments thereof.

[0091] The terms "purification", "separation" or "isolation" as used interchangeably herein refer to increasing the purity of a protein of interest from a composition or sample comprising a protein of interest and one or more impurities. Typically, the purity of a protein of interest is increased by removing (completely or partially) at least one impurity from a composition. "Purification" and its equivalents refer to one or more steps performed to separate a therapeutic protein from one or more other impurities (e.g., bulk impurities) or components present in a fluid containing a therapeutic protein (e.g., plasma, Cohn fractions, liquid culture medium proteins, or one or more other components present or secreted in mammalian cells (e.g., DNA, RNA, other proteins, endotoxins, viruses, etc.). For example, purification can be performed during or after the initial capture step. Resins, membranes, or any other solid supports that bind therapeutic proteins or contaminants can be used for purification (e.g., by using affinity chromatography, hydrophobic interaction chromatography, anion or cation exchange chromatography, or molecular sieve chromatography). At least one chromatographic column and / or chromatographic membrane (e.g., any chromatographic column or chromatographic membrane described herein) can be used to purify a therapeutic protein from a fluid containing a therapeutic protein.

[0092] For example, immunoglobulins can be purified by removing contaminating non-immunoglobulin proteins; they are also purified by removing immunoglobulins other than IgG. Removing non-immunoglobulin proteins and / or removing immunoglobulins other than IgG results in an increase in the percentage of desired IgG in the raw material. Purity can be measured by standard assays known in the art or described herein, examples of which include SDS-PAGE, followed by Coomassie blue staining and chromatographic methods (e.g., size exclusion chromatography (SEC) on an HPLC system). The purity of an IgG sample can be calculated from an SDS PAGE gel, for example, after scanning using a Kodak Image Station 1000 or an equivalent system, or by analyzing a SEC chromatogram on a Shimadzu HPLC system using software. If the sample is at least 90%, 95%, or 99% free of components other than the desired product (e.g., immunoglobulin), the sample is considered pure.

[0093] Preferably, the method produces an Ig preparation that is at least 80%, 85%, 90%, 95% or 99% or more pure. "Pure" refers to a preparation of one or more Ig isotypes in which contaminating non-Ig proteins are reduced, or it refers to a preparation of a first Ig isotype in which contaminating second isotype Ig is substantially absent. In an exemplary embodiment, the invention provides an IgG subtype preparation that is enriched for that subtype relative to a preparation of that subtype purified using protein A alone.

[0094] The term "capture" refers to a step performed to partially purify or separate (e.g., at least or about 5% by weight, e.g., at least or about 10%, 15%, 20%, 25%, 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, at least about 95%, or at least about 99% pure), optionally concentrate, and optionally stabilize a therapeutic protein relative to one or more other components present in a mixture containing a protein, e.g., a starting material containing IgG. Typically, capture is performed using a resin that binds the therapeutic protein (e.g., by using affinity chromatography). Non-limiting methods for capturing therapeutic proteins from liquids are described herein, and other methods are known in the art. The therapeutic protein can be captured from a liquid medium using at least one chromatographic column and / or chromatographic membrane (e.g., any chromatographic column and / or chromatographic membrane described herein). In an exemplary embodiment, the invention provides a method for enriching a preparation for selected Ig isotypes or IgG subtypes by capturing one or more desired isotypes and / or subtypes or one or more isotypes and / or subtypes in addition to the isotypes and / or subtypes to be enriched on an affinity column (other than Protein A).

[0095] As used herein, the term "buffer" refers to a substance whose presence in a solution increases the amount of acid or base that must be added to cause a unit change in pH. Buffer solutions resist changes in pH through the action of their acid-base conjugate components. Buffer solutions used with biological reagents are generally capable of maintaining a constant hydrogen ion concentration so that the pH of the solution is within the physiological range. Traditional buffer components include, but are not limited to, organic and inorganic salts, acids, and bases.

[0096] The term "chromatography column" or "column" as used herein in relation to chromatography refers to a container, usually in the form of a cylinder or hollow column, filled with a chromatography matrix or resin. A chromatography matrix or resin is a material that provides physical and / or chemical properties for purification.

[0097] As used herein, the term "flow-through" or "flow-through mode" refers to a general purification method in which contaminants are removed from a mixture during a chromatographic process because they are usually retained by the chromatographic process when bound to a chromatographic medium in a column. Because the protein of interest is not bound to a chromatographic medium (usually a chromatographic medium in a column) (or it is not too strongly bound compared to the contaminants), but flows directly through to be collected, it is purified. "Flow-through" also refers to a liquid collected from the chromatographic mode. After the liquid medium containing the protein of interest flows through the column, the impurities bound to the column are optionally "stripped" or removed from the column so that the column can be regenerated for another chromatographic run. This method is different from "binding and elution" or "binding and elution mode", in which the target protein of interest is retained on the chromatographic medium in the column, and the impurities flow directly through the column. Then, the process involves specific elution of the protein of interest using different column conditions, which interfere with the binding of the protein of interest to the chromatographic medium, which is usually a resin, in the column.

[0098] The term "refining" is a technical term and refers to a step performed to remove residual traces or small amounts of contaminants or impurities from a fluid containing a therapeutic protein close to the final desired purity. For example, refining can be performed by passing a fluid containing IgG through a chromatographic column or a membrane absorber that selectively binds to the IgG (target therapeutic protein) or small amounts of contaminants or impurities present in the fluid containing the target therapeutic protein. In this example, the eluate / filtrate of the chromatographic column or membrane absorber contains the therapeutic protein.

[0099] As used herein, the term "contaminant" or "impurity" is used in its broadest sense to encompass any unwanted component or compound in a mixture. Contaminant proteins include, but are not limited to, those naturally produced by donor or host cells, as well as proteins related to or derived from the protein of interest (e.g., proteolytic fragments) and other process-related contaminants. In certain embodiments, the contaminant precipitate is separated from the cell culture using another method such as centrifugation, sterile filtration, depth filtration, and tangential flow filtration. In various embodiments, the contaminant is an Ig isotype or IgG subtype other than an isotype or IgG subtype that is enriched in the preparation by implementing the method of the present invention to manufacture a preparation. Exemplary contaminants eliminated or removed in the disclosed process include one or more of albumin, apolipoprotein AI, complement C3, haptoglobin, fibrinogen, complement C4-B, complement C1s subcomponent, complement C1r subcomponent, apolipoprotein B-100, alpha-2-macroglobulin. In an exemplary embodiment, these contaminants are removed during the on-column solvent / detergent step.

[0100] The term "loading buffer" refers to a buffer used to prepare a mixture or other sample and load it into a chromatography unit.

[0101] As used herein, "eluate" refers to the liquid flowing out of a chromatography column or a chromatography membrane, which contains detectable amounts of protein.

[0102] As used herein, "therapeutic drug substance" refers to a substance containing proteins, such as IgG, which is substantially enriched, purified or separated by the methods of the invention from contaminating proteins, lipids and nucleic acids (e.g., contaminating proteins, lipids and nucleic acids present in liquid culture medium or from host cells (e.g., from mammalian, yeast or bacterial host cells) and biological contaminants (e.g., viral and bacterial contaminants). Exemplary therapeutic drug substances can be formulated into medicaments without any further substantial purification and / or cleanup steps.

[0103] The term "unit operation" refers to a functional step that can be performed in the process of the invention for making a therapeutic protein drug substance from a raw material. For example, a unit operation can be filtration (e.g., removing contaminant bacteria, yeast viruses or mycobacteria and / or specific substances from a fluid containing a therapeutic protein), capture, chromatography, purification, holding or storage, polishing, viral inactivation, adjusting the ion concentration and / or pH of a fluid containing a therapeutic protein, and / or removing unwanted salts.

[0104] In some embodiments, the chromatography system disclosed herein is on a runner. As used herein, a "runner" refers to a three-dimensional solid structure that can be used as a platform or support for the system described herein. If the runner includes one or more structures that can move (e.g., wheels, rollers, or similar structures), the runner can impart mobility to the system or a portion thereof.

[0105] The term "multi-column chromatography system" or "MCCS" refers to a system having a total of two or more interconnected or switched chromatographic columns and / or chromatographic membranes. A non-limiting example of a multi-column chromatography system is a periodic countercurrent chromatography system (PCC), which comprises a total of two or more interconnected or switched chromatographic columns and / or chromatographic membranes. Other examples of multi-column chromatography systems are described herein and are known in the art. An exemplary MCCS of the present invention comprises a protein A column connected to an affinity ligand column fluid, which itself may be directly or indirectly connected to one or more additional affinity ligand column fluids.

[0106] In some embodiments, the recovery rate of the desired protein of the method and system, such as IgG or another selected Ig isotype or IgG subtype, from the raw material is at least about 40%, 50%, 55% or 60% and up to about 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or at least about 99% of the amount of protein contained in the raw material loaded on the first column. In some embodiments, the purification recovery rate is at least about 60% to about 70%. In an exemplary embodiment, the purification recovery rate is at least about 98% or at least about 99% of the amount of protein contained in the raw material loaded on the first column. In various embodiments, the IgG purification recovery rate is at least about 98% or at least about 99% of the amount of IgG contained in the raw material loaded on the first column. In an exemplary embodiment, the purification recovery rate of one or more of IgG1, IgG2, IgG3 and / or IgG4 is at least about 98% or at least about 99% of the amount of the relevant IgG contained in the raw material loaded on the first column.

[0107] As used herein, the term "mixing" describes the act of causing distribution of two or more different compounds or substances in a solution or suspension by any form of agitation. A completely uniform distribution of all ingredients in a solution or suspension caused by the term "mixing" as used in this application is not necessary.

[0108] As used herein, the term "solvent" includes any liquid substance capable of dissolving or dispersing one or more other substances. The solvent may be inorganic in nature, such as water, or it may be an organic liquid, such as ethanol, acetone, methyl acetate, ethyl acetate, hexane, petroleum ether, etc. As used in the term "solvent detergent treatment", the solvent represents an organic solvent (e.g., tri-n-butyl phosphate) that is a part of a solvent detergent mixture for inactivating lipid enveloped viruses in solution. An exemplary solvent / detergent process is performed on a column and removes plasma protein contaminants such as those mentioned above in addition to viral-derived contaminants.

[0109] As used herein, the term "detergent" is used interchangeably with the term "surfactant" or "surface acting agent" in this application. Surfactants are typically amphiphilic, i.e., organic compounds that contain a hydrophobic group ("tail") and a hydrophilic group ("head"), making the surfactant soluble in organic solvents and water. Surfactants can be classified according to the presence or absence of a formal charged group in their head. Nonionic surfactants have no charged groups in their head, while ionic surfactants have a net charge in their head. Zwitterionic surfactants have two oppositely charged groups in their head. Some examples of common surfactants include: anions (based on sulfate, sulfonate or carboxylate anions): perfluorooctanoate (PFOA or PFO), perfluorooctane sulfonate (PFOS), sodium dodecyl sulfate (SDS), ammonium lauryl sulfate and other alkyl sulfates, sodium laureth sulfate (also known as sodium lauryl ether sulfate, or SLES), alkylbenzene sulfonates; cations (based on quaternary ammonium cations): cetyltrimethylammonium bromide (CTAB) (also known as hexadecyltrimethylammonium bromide) and other alkyltrimethylammonium salts, cetylpyridinium chloride (CPC), polyethoxylated tallowamine (POEA), benzalkonium chloride (BAC), benzethonium chloride (BZ T); long chain fatty acids and their salts: including octanoate, octanoic acid, heptanoate, caproic acid, heptanoic acid, nonanoic acid, decanoic acid, etc.; zwitterions (amphoterics): dodecyl betaine; cocamidopropyl betaine; cocoylampholyl glycinate; nonionic: alkyl poly (ethylene oxide), alkylphenol poly (ethylene oxide), copolymers of poly (ethylene oxide) and poly (propylene oxide) (commercially known as poloxamer or poloxamine), alkyl polyglucosides (including octyl glucoside, decyl maltoside), fatty alcohols (such as cetyl alcohol and oleyl alcohol), cocamide MEA, cocamide DEA, polysorbates (Tween 20, Tween 80, etc.), Triton detergent and dodecyl dimethylamine oxide. In an exemplary embodiment, the detergent is combined with a solvent, and the combination is used to perform a viral inactivation step on the protein preparation in the method of the present invention. In various embodiments, the viral inactivation step occurs while the formulation of the invention is on a chromatography column used in the methods of the invention.

[0110] As used herein, "Protein A" refers to an affinity ligand, which is a 49 kDa surface protein originally found in the cell wall of Staphylococcus aureus. The protein binds immunoglobulins and comprises five homologous Ig binding domains. Affinity chromatography media comprising immobilized Protein A are known in the art. As will be appreciated by those skilled in the art, in variations of the methods disclosed herein that are considered to be within the scope of the present invention, other affinity ligands, such as Protein G, Protein A / G, and Protein L, may be used in place of or in addition to Protein A. Those portions of the present disclosure that explicitly disclose Protein A are also relevant to embodiments in which one or more of Protein G, Protein A / G, and / or Protein L are used in place of or in addition to Protein A.

[0111] As used herein, the term "no significant elution" refers to the property of an aqueous solution when a protein immobilized on a chromatographic medium is contacted with an aqueous solution (e.g., a buffer, a solvent / detergent, or other mixture) such that no or only a very small amount of protein is eluted from the chromatographic medium by the solution. In exemplary embodiments, less than about 5%, less than about 3%, less than about 1%, or less than about 0.1% of the protein is eluted from the chromatographic medium by the solution. An exemplary solution that does not significantly elute protein is a solvent / detergent solution. An exemplary protein that is not eluted from the chromatographic medium by a solvent / detergent solution is IgG. In exemplary embodiments, "no significant elution" means that less than about 5% of the IgG immobilized on the chromatographic medium is eluted from the chromatographic medium by contact with a solvent / detergent solution.

[0112] Table entries herein marked with the symbol "x" indicate that the associated component was not analyzed.

[0113] C. Abbreviations

[0114] BDS, drug substance; CRS, frozen supernatant (supernatant after the first precipitation in COHN fractionation); CV, column volume; DFM, data file manager (protocol system); E, elution fraction; EDTA, ethylenediaminetetraacetic acid; EtOH, ethanol; Fc, antibody Fc domain; FT, flow-through; HPLC, high performance liquid chromatography; IgG, immunogamma globulin; IgG1, IgG2, IgG3, IgG4, immunogamma globulin subclasses 1–4; IQEQ, equilibration buffer (an exemplary IQEQ allows further purification of plasma proteins from the flow-through from one or more affinity columns after adsorption of IgG; e.g., 10 mM sodium acetate, 10 mM TrisHCl, 120 mM NaCl, pH 7.2); MAB, monoclonal antibody; MWCO, molecular weight cut-off; SD_VI, solvent detergent-viral inactivation, e.g., 10 mM sodium acetate, 10 mM TrisHCl, 120 mM NaCl and SD_VI_MIX Triton X 10.55 g / polysorbate 80 3.21 g / TnBP 2.91 g / kg buffer); SEC, size exclusion chromatography; TnBP, tri-n-butyl phosphate; vWF, von-Willebrand-Factor; W, wash fraction; WB, Western blot; WSD, wash solvent / detergent.

[0115] C. Implementation Plan

[0116] In an exemplary embodiment, the invention relates to an affinity chromatography method for preparing an IgG preparation from a raw material, such as an IgG-containing starting material, the preparation comprising one or more of IgG1, IgG2, IgG3 and IgG4. The method comprises (a) contacting a feedstock with a first chromatographic medium comprising a first solid support bound with protein A, thereby forming a protein A-bound fraction of IgG subclasses having protein A binding affinity, and forming a first flow-through comprising IgG subclasses not bound to protein A; (b) contacting the first flow-through with a first affinity ligand chromatographic medium comprising a second solid support having a first affinity ligand having IgG binding affinity bound thereto, thereby forming a first affinity ligand-bound IgG subclass and a second flow-through comprising IgG subclasses not bound to the first affinity ligand-bound IgG subclasses; (c) eluting the protein A-bound fraction from the first chromatographic medium, thereby forming a first eluate and contacting the first eluate with the first affinity ligand chromatographic medium, thereby forming a second affinity ligand-bound IgG subclass, and a second flow-through; and (d) eluting a member selected from the first affinity ligand-bound IgG subclass, the second affinity ligand-bound IgG subclass, and a combination thereof from the first affinity ligand column, thereby forming a second eluate.

[0117] In an exemplary embodiment, the method further comprises (e) combining the first flow-through and the second eluate on the first affinity ligand chromatography medium.

[0118] In an exemplary embodiment, the method includes (f) contacting the second eluate of (d) with a second affinity ligand chromatography medium, the second affinity ligand chromatography medium comprising a third solid support having a second affinity ligand having affinity for IgG bound thereto, thereby forming a third affinity ligand-bound IgG subclass and a second flow-through comprising a fourth IgG subclass that is not bound to the second affinity ligand chromatography medium; and (g) eluting a member selected from the second affinity ligand-bound IgG subclass, the fourth IgG subclass, and a combination thereof from the second affinity ligand chromatography medium, thereby forming a third eluate.

[0119] In an exemplary embodiment, the method includes (h) prior to (g), combining the first flow-through and the second eluate on a second affinity ligand chromatography medium.

[0120] In various embodiments, the method includes (i) prior to (b), contacting the first chromatography medium with a buffer / detergent mixture that does not elute the Protein A bound fraction of the IgG subclass having Protein A binding affinity from the first chromatography medium.

[0121] In some embodiments, the method includes (j) prior to (g), contacting the second affinity ligand chromatography medium with a buffer / detergent mixture that does not elute the second affinity ligand-bound IgG subclass from the second affinity ligand chromatography medium.

[0122] Exemplary embodiments include dedicated washing steps and solvent / detergent on column, virus inactivation step (" on column " SD_VI treatment), thereby reducing the total number of unit operations compared with traditional IgG classification and purification. The SD_VI step on column can be performed on any column in the array or more than one column. In various embodiments, by directly incorporating the SD_VI step into the established unit operation, rather than performing as an independent step to the material separated from the chromatographic medium, the SD_VI on column further enhances the effectiveness and compactness of the process of the present invention, especially with respect to standard classification procedures in the art. In fact, more unexpectedly, the purity of the IgG preparation is improved when the SD_VI step on column is incorporated into purification, because it is expected that the step will not produce an effect other than virus inactivation. The SD_VI step consumes or removes impurities other than viral-derived impurities.

[0123] In various embodiments, the SD_VI step is performed after the IQEQ step of capturing the target therapeutic protein (eg, IgG) on the chromatography medium and producing the flow-through, and before eluting the target therapeutic protein from the chromatography medium.

[0124] In an exemplary embodiment, the SD_VI step depletes or removes at least one of albumin, apolipoprotein AI, complement C3, haptoglobin, fibrinogen, complement C4-B, complement C1s subcomponent, complement C1r subcomponent, apolipoprotein B-100, alpha-2-macroglobulin. In an exemplary embodiment, these impurities are present in the wash solution from the SD_VI step.

[0125] In an exemplary embodiment, the buffer / detergent mixture comprises acetate, Tris, Triton X, tri(n-butyl) phosphate (TnBP).

[0126] In an exemplary embodiment, the buffer / detergent mixture comprises a buffer component having about 10 mM sodium acetate, about 10 mM TrisHCl, and about 120 mM NaCl, and a detergent component having about 10.55 g Triton X, 3.21 g Polysorbate 80, and about 2.91 g TnBP per kg buffer solution.

[0127] The methods and systems of the present invention provide preparations in which the IgG content is significantly enriched relative to the starting material.

[0128] In an exemplary embodiment, the IgG in the formulation comprises at least about 90% wt / wt of the protein content of the IgG formulation of the invention.

[0129] In an exemplary embodiment, IgG1 in the formulation comprises about 40% to about 90% wt / wt of the protein content of the formulation.

[0130] In an exemplary embodiment, IgG2 in the formulation comprises about 15% to about 55% wt / wt of the protein content of the formulation.

[0131] In an exemplary embodiment, IgG3 in the formulation comprises from about 0.5% to about 50% wt / wt of the protein content of the formulation.

[0132] In an exemplary embodiment, IgG4 in the formulation comprises from about 0.1% to about 20% wt / wt of the protein content of the formulation.

[0133] Exemplary methods of the invention provide highly pure IgG preparations.In various embodiments, the invention provides a highly pure preparation of an IgG isotype.

[0134] In an exemplary embodiment, the amount of albumin in the formulation is less than about 5 g / L, such as a formulation of less than about 2 g / L, less than about 1 g / L, less than about 0.4 g / L, less than about 0.2 g / L, less than about 0.1 g / L, or less than about 0.05 g / L.

[0135] In an exemplary embodiment, the Factor XI activity in the formulation is less than about 0.01 E / mLt, such as less than about 0.005 E / mLt, such as less than about 0.001 E / mLt.

[0136] In an exemplary embodiment, the amount of alpha-2-macroglobulin present in the formulation is less than about 0.2 g / L, such as less than about 0.1 g / L, such as less than about 0.05 g / L of the formulation.

[0137] In an exemplary embodiment, the amount of transferrin present in the formulation is less than about 0.4 g / L and less than about 0.2 g / L, such as less than about 0.09 g / L of the formulation.

[0138] In an exemplary embodiment, the PL1 activity of the formulation is less than about 10 nm / mL min.

[0139] In an exemplary embodiment, the amount of fibrinogen present in the formulation is less than about 60 μg / mL, less than about 35 μg / mL, such as less than about 13 μg / mL of the formulation.

[0140] In an exemplary embodiment, the IgG-containing starting material is a frozen supernatant.

[0141] In an exemplary embodiment, a member selected from a first chromatographic medium comprising a first solid support having Protein A, a first affinity ligand chromatographic medium comprising a second solid support bound to a first affinity ligand having IgG binding affinity, and combinations thereof are contained in a single column.

[0142] In an exemplary embodiment, the invention provides a system and methods of using the system, wherein two or more of the chromatographic columns comprising Protein A, one or more affinity ligand chromatographic media, and combinations thereof are fluidically connected within a column array, and two or more of the columns comprise a second chromatographic media and a second affinity ligand chromatographic media. The columns are optionally fluidically coupled via fluid inlets, fluid outlets, and conduits connecting one or more outlets from one or more columns to one or more inlets of one or more columns. The columns in the array may be fluidically connected in series, in parallel, or in a combination of these configurations.

[0143] In an exemplary embodiment, the outlet of the first column is in fluid communication with the inlet of the second column, allowing eluate from the first column to be loaded directly onto the inlet of the second column and thereby onto the chromatographic medium contained therein.

[0144] In an exemplary embodiment, the outlet of the column having Protein A is in fluid communication with the inlet of the first affinity ligand chromatography medium.

[0145] In an exemplary embodiment, the outlet of the column comprising the second chromatographic medium to which the first affinity ligand is bound is in fluid communication with the inlet of the column comprising the second affinity ligand chromatographic medium.

[0146] In various embodiments, the outlet of the first column is switchably connected to the inlet of one or more second columns. In an exemplary embodiment, the outlet of one or more first columns is switchably connected to the inlet of one or more second columns.

[0147] In an exemplary embodiment, the IgG solution lacking Protein A binding IgG subclasses comprises a member selected from the group consisting of IgG1, IgG2, IgG3, IgG4, and combinations thereof.

[0148] In another exemplary embodiment, the first chromatographic medium has a selective affinity for the CH1 domain of a human IgG antibody.

[0149] In an exemplary embodiment, the first chromatographic medium has a selective affinity for the CH1 domain of a member selected from IgG1 and IgG3 that is greater than the selective affinity for the CH1 domain of a member selected from IgG2 and IgG4.

[0150] In an exemplary embodiment, elution from the first chromatography medium, the first affinity ligand chromatography medium, and / or the second affinity ligand chromatography medium uses an eluent comprising glycine.

[0151] In an exemplary embodiment, the glycine concentration is about 50 mM to about 150 mM. In an exemplary embodiment, the glycine concentration is about 130 mM.

[0152] Other eluents may be used in the present invention including, but not limited to, citrate, acetate, MES, HCl at a pH below 4.0, and combinations thereof.

[0153] An exemplary embodiment of the present invention relates to an affinity chromatography method for preparing an IgG preparation enriched in at least a first IgG subclass with low protein A binding affinity from a plasma-derived IgG solution lacking protein A binding IgG subclasses. The method comprises (a) contacting the IgG solution lacking protein A binding IgG subclasses with a first affinity ligand chromatography medium, the medium comprising a first solid support having a first affinity ligand with IgG binding affinity bound thereto, thereby forming a first bound fraction and a first flow-through of the first IgG subclass with low protein A binding affinity; and (b) eluting the first bound fraction of the first IgG subclass with low protein A binding affinity, thereby forming a first eluate containing an IgG preparation enriched in the first IgG subclass with low protein A binding.

[0154] An exemplary source IgG solution lacking Protein A-binding IgG subclasses is prepared by passing a starting material containing IgG through a chromatography medium comprising Protein A, allowing one or more IgG subclasses having affinity for Protein A to bind, and collecting from the chromatography medium, typically in the flow-through, those IgG subclasses that do not have sufficient affinity for Protein A to remain bound to Protein A during the process.

[0155] In an exemplary embodiment, the method further comprises (c) contacting the first bound fraction of the first IgG subclass with low Protein A binding affinity with a buffer / detergent solution prior to (b), and subsequently removing the detergent solution from the first affinity ligand chromatography medium.

[0156] In an exemplary embodiment, the method further includes (d) after (b), contacting the first eluate with a second chromatographic medium, the second chromatographic medium comprising a solid support having an affinity ligand bound thereto, the ligand having affinity for a second IgG subclass with low protein A binding affinity, thereby forming a first bound fraction of the second IgG subclass with low protein A binding affinity; and (e) eluting the first bound fraction of the second IgG subclass with low protein A binding affinity from the second chromatographic medium, thereby forming a second eluate.

[0157] In some embodiments, the method further comprises (f) contacting the first bound fraction of the second IgG subclass with low Protein A binding affinity with a buffer / detergent solution prior to (e), and subsequently removing the detergent solution from the first chromatography medium.

[0158] In various embodiments, the method further comprises (g) prior to (a), contacting the plasma-derived IgG solution with a protein A chromatography medium comprising protein A bound to a solid support, thereby forming a protein A-bound fraction of IgG subclasses having a high affinity for protein A, and an IgG preparation enriched in a first IgG subclass having a low protein A binding affinity.

[0159] In an exemplary embodiment, the method further comprises (h) eluting the Protein A-bound fraction of the IgG subclass having a high affinity for Protein A from the Protein A chromatography medium, thereby forming a third eluate.

[0160] Exemplary methods include the step of combining two or more of the first eluate, the second eluate, and the third eluate.

[0161] Exemplary methods of the present invention use two, three or more columns in series. The starting protein mixture is applied to the entrance of the first column (e.g., protein A), then the washing solution of the preselected volume is passed through the column, unbound IgG and impurities are removed, and in some embodiments, the protein population in the mixture is advanced through the first column and enters one or more subsequent columns. The flow-through liquid leaving the final column is optionally collected. After the washing cycle, the eluent, which is a weakly acidic eluent in some embodiments, enters the entrance of the first column, and the protein population bound to the chromatographic medium is eluted into the second column, and the protein population bound to the chromatographic medium in the second column tube is passed through the end of the device, or in some embodiments, enters the third column filled with the third chromatographic medium, and so on. In the elution step, the protein population bound to the chromatographic medium in the first column (e.g., the second affinity ligand medium) is desorbed from the medium, enters the second column and is combined with the second chromatographic medium in the second column. The same is true for proteins adsorbed to the second medium, which are desorbed and enter the third column in embodiments where a third column is present, and are optionally collected at the end of the second column in those embodiments where a third column is not present, or collected at the end of the third column. The above process is optionally repeated for the third column and subsequent columns.

[0162] In an exemplary embodiment, the flow-through and / or eluate from each column or subset of columns can be collected or pooled separately before loading onto subsequent columns. Embodiments using a combination of columns in series and one or more separate columns are also within the scope of the invention.

[0163] Also provided herein are IgG preparations prepared by the methods of the present invention. In an exemplary embodiment, the preparation has an IgG subtype profile that is substantially consistent with human plasma. In an exemplary embodiment, the preparation has an impurity profile that is substantially consistent with human plasma. In an exemplary embodiment, the preparation has an IgG subtype profile and an impurity profile that are substantially consistent with commercial polyclonal IgG preparations such as Gammagard liquid, Kiovig, and Cuvitru.

[0164] The aqueous IgG solution according to the invention may be further processed by one or more ion exchange steps and by formulating it into a final pharmaceutically acceptable preparation.

[0165] In an exemplary embodiment, an aqueous IgG solution is provided, comprising at least about 99.5% IgG and less than about 0.5% impurities, wherein the aqueous IgG solution comprises less than about 0.0025E / mg total IgG, preferably less than about 0.0020E / mg total IgG, more preferably less than about 0.0015E / mg total IgG, and most preferably less than about 0.0012E / mg total IgG of active factor XI as an impurity.

[0166] In an exemplary embodiment, an aqueous IgG solution is provided, comprising at least about 99.5% IgG and less than about 0.5% impurities, wherein the aqueous IgG solution comprises complement C3 as an impurity at a level of less than about 3.5 μg / mg total IgG, preferably less than about 3.0 μg / mg total IgG, more preferably less than about 2.5 μg / mg total IgG, and most preferably less than about 2.2 μg / mg total IgG.

[0167] In an exemplary embodiment, an aqueous IgG solution is provided, comprising at least about 99.5% IgG and less than about 0.5% impurities, wherein the aqueous IgG solution comprises complement C3 and factor XI as impurities, wherein complement C3 is present at a level of less than about 3.5 μg / mg total IgG, preferably less than about 3.0 μg / mg total IgG, more preferably less than about 2.5 μg / mg total IgG, and most preferably less than about 2.2 μg / mg total IgG, and wherein factor XI is present at an activity of less than about 0.0025E / mg total IgG, preferably less than about 0.0020E / mg total IgG, more preferably less than about 0.0015E / mg total IgG, and most preferably less than about 0.0012E / mg total IgG. In an exemplary embodiment, an aqueous IgG solution is provided that comprises at least about 99.5% IgG and less than about 0.5% impurities, wherein the aqueous IgG solution comprises complement C3 and factor XI as impurities, wherein complement C3 is present at a level of less than about 2.5 μg / mg total IgG, and wherein factor XI is present at an activity of less than about 0.0015E / mg total IgG.

[0168] The following examples are used to illustrate certain exemplary embodiments of the present invention and should not be construed as limiting the scope of the present invention in any way. The ability of the affinity purification method to develop a next generation human IgG product that is equivalent to or better than the currently available IgG product has been assessed. To date, affinity purification has not been used on a large scale to replace classification in order to purify IgG or other proteins from the starting material containing IgG.

[0169] Example

[0170] Example 1

[0171] 1.1 Experimental Overview

[0172] Initial experiments were performed using purified plasma-derived polyclonal IgG as starting material. The goal was to quickly gather information using an established IgG product already in clinical use as a benchmark.

[0173] In the first screening, several potential candidates for the second affinity purification step were evaluated as independent chromatography runs run in parallel. Regarding the tandem approach, it was further performed as follows:

[0174] 1. Capture the major portion of IgG with protein A derivatized resin

[0175] 2. Use of a surrogate IgG binding affinity resin to capture residual IgG present in the flow-through (FT) of the Protein A capture

[0176] In the next step, the resin with the best binding properties (capacity) was selected for additional experimental setup. In this approach, the capture of IgG from frozen supernatants was evaluated.

[0177] The first set of experiments was designed to screen combinations of Protein A and resins to capture the full range of IgG subclasses in a "tandem" array. Liquid purified plasma-derived polyclonal IgG preparations were used as starting material.

[0178] The second set of experiments was designed to optimize the IgG subclass panel directly using modified Cohn frozen supernatant as starting material.

[0179] 1.2 Biomaterials

[0180] 1. Purified plasma-derived polyclonal IgG

[0181] 2. Freezing of supernatant

[0182] 1.3 Buffer

[0183] All buffers used in the experiments were prepared in the operating department. Buffers were stored at +2 to +8°C.

[0184] 1.4 Resin selection

[0185] For direct capture, Mab select PrismA (GE Healthcare) was chosen due to its high tolerance to sodium hydroxide.

[0186] The frozen supernatant contains all coagulation factors except FVIII and vWF, which are reduced after cryoprecipitation. This fact may lead to partial coagulation and precipitation on the resin, thus requiring effective regeneration and cleaning procedures.

[0187] The resin selected for capturing the residual IgG subpopulation was a commercially available chromatography resin supplied by Thermo Fisher.

[0188] Table 1. List of resins screened for improved IgG capture

[0189] Resin <![CDATA[1.CaptureSelect TM FcXL Affinity Matrix]]> <![CDATA[2.CaptureSelect TM CH1-XL Affinity Matrix]]> <![CDATA[3.CaptureSelect TM KappaXL Affinity Matrix<!-- 19 --> ]]> <![CDATA[4.CaptureSelect TM IgG-Fc(ms) Affinity Matrix]]> <![CDATA[5.CaptureSelect TM LC-Lambda(Hu) Affinity Matrix]]> <![CDATA[6.CaptureSelect TM KappaXP Affinity Matrix]]> <![CDATA[7.CaptureSelect TM IgG3 Affinity Matrix*]]>

[0190] *Not used in the screening phase due to the ability of Capture Select CH1-XL, FcXL and FcMS to bind ≥97% of IgG3 in a purified polyclonal IgG solution.

[0191] 1.5 Evaluation of single unit operations / clusters

[0192] Table 2. Buffers used in the screening phase

[0193]

[0194] 1.6 Chromatographic scheme for stage 1 (Prisma affinity)

[0195] A column with the following dimensions was used for the Protein A capture step:

[0196] Column: 3.2 cm h = 7.5 cm A = 8.04 cm 2 V=60.3ml

[0197] Table 3. Chromatographic scheme IG_MAX

[0198]

[0199]

[0200] 1.7 Results of the screening phase / experiments

[0201] a. Affinity of starting material containing purified IgG for MAb Select PrismA

[0202] The chromatography run on the Protein A capture column was performed as previously outlined in the chromatography protocol for Stage 1, with a calculated column load of 30 mg IgG / ml resin.

[0203] exist Figure 1 In , the flow-through UV profile is shown. In this experimental setup using IgG-containing starting material, the low extinction provides information about the high binding efficiency of human IgG.

[0204] Flowthrough fractions (UV 280 signal) of a PrismA run using IgG containing starting material.

[0205] This flow-through fraction was collected and used as a load for further screening of affinity resins with different specificities for immunoglobulin subgroups as described in the selection of resins.

[0206] 1.8 IgG content and subclass distribution of the load and flow-through (FT) fractions of MabSelect PrismA resin

[0207] Table 4. Run IGR01: IgG1, IgG2, IgG3, and IgG4 in the “flowthrough (FT)”

[0208] IgG1 IgG2 IgG3 IgG4 Load [mg] 1218.5 547.1 52.03 65.42 FT[mg] 18.6 <0.1 33.4 <0.1 <![CDATA[% in FT 2 > 1.5 <0.1 64.2 <0.1

[0209] . 1 Based on ratios where IgG3 is 1 part / ratios are given as x times parts of IgG3

[0210] . 2Percentage of IgG subclasses found in PrismA flowthrough

[0211] Only significant amounts of IgG3 were found in the flow-through of Mab Select PrismA.

[0212] Example 2

[0213] 2.1 Chromatographic scheme for stage 2 (resin screening)

[0214] A column with the following dimensions was used for the resin scouting run using the Protein A capture flow-through:

[0215] Column: 10 cm h = 3 to 4 cm A = 0.79 cm 2 V = 3.5 to 4.5 ml

[0216] The chromatographic procedures for these runs are listed under Chromatographic Procedures for Resin Screening Runs.

[0217] 2.2 Chromatographic Procedure for Resin Screening Runs

[0218] Table 5. Chromatographic scheme for resin screening

[0219]

[0220] 2.3Capture Select Flowthrough Evaluation UV 280nm Signal

[0221] Figure 2 The flowthrough profiles of the screened resins are shown. Different UV 280 signal heights were observed for, for example, anti-λ or anti-CH1-XL. Lower flowthrough UV levels resulted in higher UV elution peaks.

[0222] 2.4 Capture Select eluent to evaluate UV280 nm signal

[0223] Figure 3 The elution profiles of the screened resins are shown. Different UV280 signal heights and areas were observed. CaptureSelect CH1-XL showed the highest peak and the largest peak area.

[0224] Based on these data, the CaptureSelect resins were ranked. The most effective resin was CaptureSelect CH1-XL.

[0225] 2.5 Data Evaluation

[0226] a. Summary of peak areas of the Capture Select affinity eluate from the PrismA flowthrough containing the purified IgG starting material

[0227] Table 6 shows the peak areas (UV280 nm) of the different affinity columns tested. The results of the analysis of the Protein A resin are listed under the IgG content and subclass distribution of the load and flow-through (FT) fractions of the MabSelect PrismA resin. IgG2 and IgG4 were almost quantitatively captured, with lower capture efficiencies for IgG1 and IgG3. These subtypes were captured by the second resin. CaptureSelect CH1-XL was identified as binding most of the residual IgG subspecies of the Mab Select PrismA flow-through. The resin was introduced as a second column to run subsequent experiments.

[0228] Table 6. Chromatogram evaluation (peak area)

[0229]

[0230] Example 3

[0231] 3.1 Evaluation of Remaining IgG Subclasses in the Flowthrough of Capture Select Resin-Bound Mab Select PrismA

[0232] In the table below, the recovery of IgG1 and IgG3 from the flow-through fraction of Mab select PrismA using different Capture Select columns is summarized. Only the flow-through and elution fractions are listed. Some may be in the flow-through fraction (below the detection limit) and in the wash and post-elution fractions (not analyzed).

[0233] Table 7. Capture Select CH1 XL Run Number: CH1XL

[0234] IgG1 IgG1 IgG3 IgG3 load 2.97mg 100% 5.33mg 100% FT Below detection limit na Below detection limit na Eluent 2.54mg 85.4% 3.77mg 70.8%

[0235] na = not applicable

[0236] Table 8. Capture Select KAPPA XL Run No.: KAPPA XL

[0237] IgG1 IgG1 IgG3 IgG3 load 2.38mg 100% 4.27mg 100% FT Below detection limit na 0.94mg 22.1% Eluent Below detection limit na 1.28mg 30.0%

[0238] na = not applicable

[0239] Table 9. Capture Select LC_LAMBDA(Hu) Run No.: LAMBDA(Hu)

[0240] IgG1 IgG1 IgG3 IgG3 load 2.88mg 100% 5.17mg 100% FT Below detection limit na 1.88mg 36.3% Eluent 1.66mg 57.7% 1.19mg 22.9%

[0241] na = not applicable

[0242] Table 10. Capture Select FcXL Run Number: FcXL

[0243] IgG1 IgG1 IgG3 IgG3 load 2.52mg 100% 4.52mg 100% FT Below detection limit na 0.02mg 2.8% Eluent 2.17mg 86.0% 2.94mg 65.0%

[0244] na = not applicable

[0245] Table 11. Capture Select KAPPA XP Run Number: KAPPA_XP_P

[0246] IgG1 IgG1 IgG3 IgG3 load 2.90mg 100% 5.20mg 100% FT Below detection limit na 1.53mg 29.4% Eluent 2.96mg 102.0% 2.89mg 55.7%

[0247] na = not applicable

[0248] Table 12. Capture Select FcMS Run No.: FcMS

[0249] IgG1 IgG1 IgG3 IgG3 load 2.37mg 100% 4.25mg 100% FT Below detection limit na 0.12mg 2.8% Eluent 1.91mg 80.7% 2.88mg 67.8%

[0250] na = not applicable

[0251] Example 4

[0252] 4.1 Variant IGC02

[0253] a. Buffer composition used in IGC02

[0254] Table 13. Buffer composition

[0255]

[0256]

[0257] 4.2 IGC02 Operation

[0258] IGC02 was performed in two steps – first affinity was performed on MAB Select PrismA and as a second step the MAB Select PrismA flow-through was applied to Capture Select CH1_XL.

[0259] Frozen supernatants from the Cohn fractionation process were introduced into the purification process without any further treatment prior to experiments.

[0260] a. First step

[0261] MAB-Select PrismA (GE Healthcare, catalog number: 17-5498-02, ID: 3.2 cm h = 7.5 cm A = 8.04 cm) was added with IQEQ buffer. 2After equilibration with 4% paraformaldehyde (V=60.3 ml), the frozen supernatant was applied to the column with a contact time of approximately 6 min.

[0262] After loading, the first wash was performed using 2CV buffer IQEQ to remove unbound proteins in the resin (added to the flow-through). SD_VI column processing was performed by applying IQEQ_VI buffer, which contained a detergent composition of 10.55gTriton X-100, 3.21g polysorbate 80 and 2.91g TnBP in 1kg IQEQ buffer (corresponding to 1% / 0.3% / 0.3% Triton X100 / polysorbate 80 / TnBP). SD_VI on the column was run by contacting the binding protein with IQEQ_VI buffer at a flow rate of 4ml / min for at least about 60 minutes in 4CV. Washing solution was optionally collected for analysis.

[0263] Wash 2 was performed using IQEQ buffer to further eliminate impurities and clean the SD_VI reagent at 10 CV and a flow rate of 10 ml / min. The wash solution was optionally collected for analysis.

[0264] Elution was performed by applying 5 CV of E1 buffer (100 mM glycine, pH 3.2).The first step of the cleaning procedure (stripping) was performed using E2 buffer (100 mM glycine, pH 2.7).

[0265] After re-equilibration with 4 CV of IQEQ buffer, the column was regenerated and stored.

[0266] The regeneration procedure and storage are described in Regeneration Procedure.

[0267] Example 5

[0268] 5.1 columns

[0269] MAB Select PrismA

[0270] GE Healthcare, catalog number: 17-5498-02

[0271] Batch number: 10264190

[0272] ID:3.2cm h=7.5cm A=8.04cm 2 V = 60.3 ml (target)

[0273] Table 14. Chromatographic scheme

[0274]

[0275] a. Chromatogram IGC02

[0276] See also Figure 4 .

[0277] 5.1 Second Step IGC01S

[0278] Capture Select CH1-XL (Thermo Fisher, catalog number: 2943452050, ID: 1.0 cm h = 3.8 cm A = 0.79 cm) was washed with IQEQ buffer. 2 After equilibration with 1% 4% ethanol (V=3.0 ml), MAB Select PrismA flow-through (IGC02) was applied to the column with a contact time of approximately 10 min.

[0279] After loading, the first wash was performed using 5 CV buffer IQEQ to remove unbound proteins from the resin (added to the flow-through). SD_VI column treatment was performed by applying IQEQ_VI buffer, which contained a detergent composition of 10.55 g Triton X-100, 3.21 g polysorbate 80 and 2.91 g TnBP in 1 kg IQEQ buffer. SD_VI column was performed by contacting the binding protein with IQEQ_VI buffer at a flow rate of 0.3 ml / min for at least 60 minutes in 10 CV (100 min).

[0280] Wash 2 was performed using IQEQ buffer to further eliminate impurities and clean the SD_VI reagent at 20 CV and a flow rate of 0.8 ml / min.

[0281] Elution was performed by applying 10 CV of E2 buffer (100 mM glycine, pH 2.7).

[0282] After re-equilibration with 10 CV of IQEQ buffer, the column was regenerated and stored.

[0283] The regeneration procedure and storage are described in Regeneration Procedure.

[0284] 5.2 columns

[0285] Capture Select CH1XL

[0286] Thermo Fisher, catalog number: 2943452050

[0287] Batch number: 170426-01

[0288] ID:10cm h=3.8cm A=0.79cm 2 V=3.0ml

[0289] Table 15. Chromatographic scheme

[0290]

[0291] a. Chromatogram IGC01S

[0292] See also Figure 5 .

[0293] 5.3 Results of running IGC02

[0294] Table 16. IGC02 IgG1, IgG2, IgG3 and IgG4 in "PrismA Flowthrough (FT)"

[0295] IgG1 IgG2 IgG3 IgG4 Load [mg] 761.5 338.2 51.66 65.77 FT[mg] 34.43 <![CDATA[x a ]]> 36.36 <![CDATA[x a <!-- 25 -->]]> <![CDATA[% in FT 2 > 4.5% <![CDATA[x a ]]> 70.4% <![CDATA[x a ]]>

[0296] . 1 Based on ratios where IgG3 is 1 part / ratios are given as x times parts of IgG3

[0297] . 2 Percentage of IgG subclasses found in PrismA flowthrough

[0298] Only significant amounts of IgG3 were found in the flow-through of Mab Select PrismA.

[0299] x a Values ​​below the detection limit

[0300] Table 17. IgG1 and IgG3 on Capture Select CH1_XL

[0301]

[0302] x a Values ​​below the detection limit

[0303] {Note: This column captures essentially all IgG1 and IgG3}

[0304] Example 6

[0305] 6.1 Variant IGC04

[0306] a. Buffer composition used in Example 6

[0307] Table 18. Buffer composition

[0308]

[0309] 6.2IGC04

[0310] The frozen supernatant from Cohn was the starting material for the purification process without any further treatment prior to the experiments. The experiments were performed at +2 to +8°C.

[0311] In the balanced tandem MAB-Select PrismA (GE Healthcare, catalog number: 17-5498-02, ID: 3.2 cm h = 7.5 cm A = 8.04 cm 2 V=60.3ml) and Capture Select CH1-XL Thermo Fisher, catalog number: 2943452050) ID: 2.2cm h=3.6cm A=3.81cm 2 After V = 13.7 ml (the flow-through of the first column was directly loaded onto the second column), the frozen supernatant was applied to the column, and the contact time on the CH1-XL column was approximately 6 min [2.3 ml / min].

[0312] After loading, the first wash was performed using 2CV buffer IQEQ to remove unbound proteins from the resin. SD_VI column treatment was performed by applying IQEQ_VI buffer, which contained a detergent composition of 10.55g Triton X-100, 3.21g polysorbate 80 and 2.91g TnBP in 1kg IQEQ buffer (the components of the detergent composition were mixed for about 15 minutes; subsequently added to the IQEQ buffer under mixing). SD_VI on the column was run by contacting the binding protein with IQEQ_VI buffer at a flow rate of 4ml / min in 4CV for a minimum of 60 minutes. For the SD_VI step: 16.6g / Kg SD_VI_MIX was added to 10mM sodium acetate, 10mM TrisHCl, 120mM NaCl, pH 7.2. SD_VI_MIX was prepared by mixing detergent / solvent at a ratio of 10.55 g Triton X100 / 3.21 g Polysorbate 80 / 2.91 g TnPB (tri-n-butyl phosphate) for at least 15 min and adding it to the buffer with mixing.

[0313] Wash 2 was performed using W2 buffer to further eliminate impurities and wash off the SD_VI reagent at 5CV and a flow rate of 10 ml / min. The third and final wash step was performed by applying 6CV of IQEQ buffer at a flow rate of 10 ml / min.

[0314] Elution was performed by applying 5 CV of E1 buffer (100 mM glycine, pH 3.2).

[0315] The first step of the cleaning procedure (stripping) was performed using E2 buffer (100 mM glycine, pH 2.7).

[0316] After re-equilibration with 4 CV of IQEQ buffer, the columns were regenerated and stored individually.

[0317] CV is the total volume of two columns (CH1-XL and Capture Select CH1-XL).

[0318] The regeneration procedure and storage are described in Regeneration Procedure.

[0319] Example 7

[0320] The eluate from Example 6 (IGC04) was processed as follows. The example is described as Example 6 - Variant IGC04.

[0321] 7.1 Series Column Array

[0322] a. Column 1

[0323] MAB Select Prism A

[0324] GE Healthcare, catalog number: 17-5498-02

[0325] Batch number: 10264190

[0326] ID:3.2cm h=7.5cm A=8.04cm 2 V = 60.3 ml (target)

[0327] b. Column 2

[0328] Capture Select CH1XL

[0329] Thermo Fisher, catalog number: 2943452050

[0330] Batch number: 170426-01

[0331] ID:2.2cm h=3.6cm A=3.81cm 2 V=13.7ml

[0332] Column volume 1+2: 74.0 ml programmed: 74.506 (column 1+2+connection - defined as 1CV)

[0333] Table 19. Chromatographic scheme

[0334]

[0335]

[0336] Column volume 1+2: 74.0 ml programmed: 74.506 (column 1+2+connection - defined as 1CV)

[0337] *Contact time on column is about 6 minutes

[0338] Fraction WSD was sampled and analyzed in detail. Fractions W2 and W3 were sampled and analyzed in SDS PAGE silver staining.

[0339] c. Chromatogram IGC04

[0340] See also Figure 6 .

[0341] 7.2 Results and data of Example 7

[0342] Table 20. Concentration of IgG as determined by immunoassay (ELISA)

[0343] Fraction load FT Eluent Stripping IgG concentration 4.92mg / ml 0.23mg / ml 8.70mg / ml 0.03mg / ml

[0344] Table 21. Yield IgG subclass distribution load and eluate

[0345] Subclass scope load Eluent Step yield IgG 1 50–70% 62.3% 65.8% 87.1% IgG 2 26.7–37.3% 28.1% 28.2% 82.6% IgG 3 >2.5% 6.4% 2.6% 34.0% IgG 4 >2.5% 3.2% 3.4% 86.3% IgA na 100% 12.0% 12.0% IgG na 100% 92.9% 92.9% IGM na 100% 22.5% 22.5%

[0346] na = not applicable

[0347] Product / Impurity Profile

[0348] LC-MS data were generated for the protein profiles of IMAX_FC_CRS_04WSD (wash buffer containing SD_VI reagent) and eluent IMAX_FC_CRS_04 (eluent of two columns MAB Select Prism A and Captur Select CH1_XL in series), which represents the intermediate product fraction after affinity purification. The impurity profile of the virus inactivated wash fraction on the SD_VI column and the product / impurity profile of the eluent were determined by RP-HPLC-ESI-MS / MS. The samples were precipitated with TCA, reduced, alkylated, digested with trypsin, and subsequently analyzed with a ThermoUltiMate Cap-HPLC coupled to an Eclipse Orbitrap (RP-HPLC-ESI-MSMS analysis). The data were analyzed using the "Proteome Discoverer" software. The results include protein composition and relative protein abundance (label-free quantification) for each sample.

[0349] result

[0350] The results are listed in Tables 22 and 23. All different immunoglobulin variants detected were combined into one protein entry "Immunoglobulin" and all corresponding area percentage values ​​were summarized. The accession numbers are from UniProt KB. An area % value of 0.00% means that the protein can be detected and identified, but the relative amount is below the critical value of 0.01%.

[0351] in conclusion

[0352] Fraction IMAX_FC_CRS_04WSD ("wash fraction") contains impurities eliminated during SD_VI on the column. The "wash fraction" sample has a protein composition of 66.96% immunoglobulins and 33.04% other proteins. 150 different proteins can be detected and identified. (Table 22). Serum amyloid A-2 protein, isoprenylcysteine ​​oxidase 1, leucine-rich alpha-2 glycoprotein, coagulation factor XI, proteoglycan 4, carboxypeptidase B2, sex hormone binding globulin, adiponectin, hyaluronan binding protein 2, neutrophil defensin 1, Ras-related protein Rap-1b, transforming growth factor-β induced protein ig-h3, integrin β-3, properdin or carboxypeptidase N catalytic chain in WSD are essentially 0%.

[0353] The "Eluate" sample had a protein composition of 99.57% immunoglobulins and 0.43% other proteins. 26 different proteins could be detected and identified. (Table 23). The Eluate represents a highly pure human IgG pool (>99%) and is of higher quality than currently commercially available IgG products. The Affinity Eluate contained essentially 0% alpha-1-acid glycoprotein 2, transthyretin, apolipoprotein B-100, C4b binding protein alpha chain, fibronectin, histidine-rich glycoprotein, complement C5, or pregnancy zone proteins.

[0354] Table 22. Impurity profile of WSD (wash fraction)

[0355]

[0356]

[0357]

[0358]

[0359] Table 23. Product / Impurity Profile of Affinity Elution Buffer E1

[0360]

[0361]

[0362] Table 24. Impurity profile of affinity eluate (LC-MS run IMAX_FC_CRS_04)

[0363]

[0364] a. Overview of SDS PAGE silver staining

[0365] See also Figure 7 .

[0366] Example 8 8.1

[0368] a. Buffer composition used in Example 8

[0369] Table 25. Buffer composition

[0370]

[0371]

[0372] 8.1. Run

[0373] The frozen supernatant from the Cohn fractionation process was used as the starting material for the purification process without any further treatment before the experiment. In a balanced tandem MAB-Select PrismA (GE Healthcare, catalog number: 17-5498-02, ID: 3.2 cm h = 7.5 cm A = 8.04 cm 2 V=60.3ml) and Capture Select CH1-XL (Thermo Fisher, catalog number: 2943452050, ID: 2.2cm h=3.6cm A=3.81cm 2 V=13.7ml) and Capture Select IgG3 (Thermo Fisher, catalog number: 191304010, ID: 2.2cm h=3.1cm A=3.81cm 2 After an array of 3 columns with a V = 11.8 ml), the frozen supernatant was applied to the column with a contact time of about 6 min [2.3 ml / min] on the CH1-XL column.

[0374] After loading, the first wash was performed using 2CV buffer IQEQ to remove unbound proteins from the resin. SD_VI on-column treatment was performed by applying IQEQ_VI buffer, which contained a detergent composition of 10.55g Triton X-100, 3.21g polysorbate 80 and 2.91g TnBP in 1kg IQEQ buffer. SD_VI on-column was performed by contacting the bound protein with IQEQ_VI buffer at a flow rate of 4ml / min for at least 60 minutes in 4CV.

[0375] Wash 2 was performed using W2 buffer to further eliminate impurities and wash off the SD_VI reagent at 5CV and a flow rate of 10 ml / min. The third and final wash step was performed by applying 6CV of IQEQ buffer at a flow rate of 10 ml / min.

[0376] Elution was performed by applying 5CV of E1 buffer (100 mM glycine, pH 3.2). The first step of the cleaning procedure (stripping) was performed using E2 buffer (100 mM glycine, pH 2.7). After re-equilibration with 4CV of IQEQ buffer, the columns were regenerated and stored separately.

[0377] 8.2Tridem column array:

[0378] a. Column 1

[0379] MAB Select Prism A

[0380] GE Healthcare, catalog number: 17-5498-02

[0381] Batch number: 10264190

[0382] ID:3.2cm h=7.5cm A=8.04cm 2 V=60.3ml

[0383] b. Column 2

[0384] Capture Select CH1XL

[0385] Thermo Fisher, catalog number: 2943452050

[0386] Batch number: 170426-01

[0387] ID:2.2cm h=3.6cm A=3.81cm 2 V=13.7ml

[0388] c. Column 3

[0389] Thermo Fisher, catalog number: 191304010

[0390] Batch number: 151012-01

[0391] ID:2.2cm h=3.1cm A=3.81cm 2 V=11.8ml

[0392] Column volume 1+2+3: 85.8 ml Programming: 86.4 (column 1+2+3+connection)

[0393] 8.3 Chromatogram

[0394] See also Figure 8 .

[0395] 8.4 Operation results and data

[0396] a. Yield IgG subclass distribution load and eluate

[0397] The Tridem array provides a highly efficient method to purify the Cohn fraction into an IgG pattern comparable to the plasma IgG subclass distribution. The ratio of IgG subclasses is nearly identical to the pattern in commercial IVIG products. Only the amount of IgG4 is higher. SDS-PAGE silver staining confirmed the high purity of the affinity eluate.

[0398] Table 26. Yield IgG subclass distribution load and eluate

[0399]

[0400] *Reference, human serum

[0401] b. Impurity profile of affinity eluent

[0402] Table 27. Impurity profile of affinity eluate (LC-MS run IMAX_FC_CRS_06)*

[0403] Impurities Eluent load albumin <0.335g / L x Factor XI <0.01E / ml 0.93E / ml α2-macroglobulin <0.185g / L x Transferrin <0.0884g / L x PL1 activity <10nm x Fibrinogen 13.0μg / ml x Amidolyt S2222 <5nm / ml min 6.51nm / ml min Amidolyt S2251 <5nm / ml min 5.56nm / ml min Amidolyt S2288 <5nm / ml min 10.9nm / ml min Amidolyt S2302 <5nm / ml min 7.45nm / ml min C3 ELISA 4.8μg / ml x

[0404] *Three immunoaffinity columns in series

[0405] b. Overview of SDS PAGE silver staining

[0406] See also Fig. 9 .

[0407] A broad pattern of IgG subclasses is obtained from IgG-containing starting material (frozen supernatant, Gammagard liquid) by using a combination of two and / or three columns containing complementary immunoglobulin binding resins in series. The purity of the resulting intermediate (eluate) is surprisingly high, comparable to affinity purification steps used in monoclonal antibody purification.

[0408] Example 9

[0409] 9.1 Equipment

[0410] For these experiments, we used The system was equipped with probes capable of online monitoring of UV absorption (2 mm flow cell), conductivity, pressure, temperature and pH, and electronic recording. The chromatography unit was operated using the system software Unicorn 7.3.

[0411] Table 28. Chromatographic Slide Device

[0412]

[0413] 9.2 Regeneration Procedure

[0414] a. Capto Select PRISM A is typically regenerated using 1M NaOH by applying 2CV for a total time of 30 minutes.

[0415] Table 29. Regeneration sequence after STRIP PRISM A (100 mM glycine pH 2.7) CV: 60 ml

[0416]

[0417]

[0418] b. Capture Select CH1-XL was regenerated using 50% (w / w) ethylene glycol, 10% (w / w) ethanolamine, 0.1% polysorbate 80, pH 8.5 (PDAM buffer) using 4 CV for a total time of 60 minutes.

[0419] Table 30. Regeneration sequence after STRIP CH1_XL (100 mM glycine pH 2.7) CV: 15 ml

[0420] Chromatographic steps Buffer / Sample Inlet valve CV Flow rate (ml / min) Outlet valve Fraction balance IQEQ A1 2 2 -- waste regeneration PDAM S1 4 1 -- waste balance IQEQ A1 5 2 -- waste store IQEQ_VI A2 5 2 --- waste

[0421] In US10,125,189 (Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use); US 9,468,675 (Removal of serine proteases by treatment with finely divided silicon dioxide); US 8,993,734 (Method to produce an immunoglobulin preparation with improved yield); US 9,782,477 (Fraction I-IV-1 precipitation of immunoglobins from plasma); US20150133636 (Purification of Biological Molecules); US 20170218012 (Integrated Continuous Manufacturing of Therapeutic Protein APIs); of Therapeutic Protein Drug Substances)) includes techniques and processes that can be used together with or in addition to the affinity chromatography production processes disclosed herein. All of the aforementioned references are incorporated herein by reference in their entirety.

[0422] Although the present invention has been described with reference to specific exemplary embodiments and examples, it should be understood that the embodiments disclosed herein are for illustrative purposes only and that various modifications and variations may be made by those skilled in the art without departing from the spirit and scope of the present invention as set forth in the appended claims.

[0423] References

[0424] All references cited herein, including the references below, and including, but not limited to, all patents, patent applications, and non-patent literature cited below or elsewhere in the specification, are hereby incorporated by reference in their entirety.

[0425] 1)DOI:105772 / 36427Affinity Chromatography for Purification of IgGfrom Human Plasma,Hofbauer L.et al.

[0426] 2)US8945895B2 Methods of purifying recombinant ADAMTS13 and otherproteins and compositions thereof.

[0427] 3)WO2019133677Adeno-associated virus purification methods.

Claims

1. An affinity chromatography method for preparing an IgG preparation from a starting material containing IgG, wherein the preparation comprises one or more of IgG1, IgG2, IgG3 and IgG4, the method comprising: (a) contacting the IgG-containing starting material with a first chromatography medium, the first chromatography medium comprising a first solid support bound to protein A, thereby forming a protein A-bound fraction of IgG subclasses having protein A binding affinity, and forming a first flow-through comprising IgG subclasses not bound to protein A; (b) contacting the first flow-through with a first affinity ligand chromatography medium, the first affinity ligand chromatography medium comprising a second solid support, the second solid support having bound thereto a first affinity ligand having binding affinity for IgG, thereby forming a second flow-through comprising IgG subclasses bound by the first affinity ligand and IgG subclasses not bound by the IgG subclasses bound by the first affinity ligand; (c) eluting the Protein A bound fraction from the first chromatography medium, thereby forming a first eluate and contacting the first eluate with the first affinity ligand chromatography medium, thereby forming a second affinity ligand-bound IgG subclass, and a second flow-through; and (d) eluting a member selected from the group consisting of the IgG subclass to which the first affinity ligand binds, the IgG subclass to which the second affinity ligand binds, and a combination thereof from the first affinity ligand column to form a second eluate.

2. The method of claim 1, wherein the first flow-through and the second eluate are combined on the first affinity ligand chromatography medium.

3. The method according to claim 2, further comprising: (e) contacting the second eluate of (d) with a second affinity ligand chromatography medium comprising a third solid support having bound thereto a second affinity ligand having affinity for IgG, thereby forming a second flow-through comprising the third affinity ligand-bound IgG subclass and a fourth IgG subclass not bound to the second affinity ligand chromatography medium; and (f) eluting a member selected from the IgG subclass to which the second affinity ligand binds, the fourth IgG subclass, and a combination thereof from the second affinity ligand chromatography medium to form a third eluate.

4. The method of claim 3, wherein the first flow-through and the second eluate are combined on the second affinity ligand chromatography medium.

5. The method according to claim 1, further comprising: (g) prior to (b), contacting the first chromatography medium with a buffer / detergent mixture that does not elute the Protein A bound fraction of the IgG subclass having Protein A binding affinity from the first chromatography medium.

6. The method according to claim 3, further comprising: (h) prior to (f), contacting the second affinity ligand chromatography medium with a buffer / detergent mixture that does not appreciably elute the IgG subclass bound by the second affinity ligand from the second affinity ligand chromatography medium.

7. The method of claim 5 or 6, wherein the buffer / detergent mixture comprises acetate, Tris, Triton X, tri(n-butyl) phosphate (TnBP).

8. The method of claim 7, wherein the buffer / detergent mixture comprises: A buffer component having about 10 mM sodium acetate, about 10 mM TrisHCl, and about 120 mM NaCl, and a detergent component having about 10.55 g Triton X, 3.21 g Polysorbate 80, and about 2.91 g TnBP / kg buffer solution (about 16.6 g SD_VI reagent relative to 1 kg buffer).

9. The method of any one of the preceding claims, wherein the IgG in the preparation comprises at least about 90% (wt / wt) of the protein content of the preparation.

10. The method of any one of the preceding claims, wherein IgG1 in the formulation comprises about 40% to about 90% (wt / wt) of the protein content of the formulation.

11. The method of any one of the preceding claims, wherein IgG1 in the formulation comprises about 50% to about 70% (wt / wt) of the protein content of the formulation.

12. The method of any one of the preceding claims, wherein IgG2 in the formulation comprises about 10% to about 50% (wt / wt) of the protein content of the formulation.

13. The method of any one of the preceding claims, wherein IgG2 in the formulation comprises about 27% to about 37% (wt / wt) of the protein content of the formulation.

14. The method of any one of the preceding claims, wherein IgG3 in the formulation comprises from about 0.1% to about 50% (wt / wt) of the protein content of the formulation.

15. The method of any one of the preceding claims, wherein IgG3 in the formulation comprises about 0.5% to about 8% (wt / wt) of the protein content of the formulation.

16. The method of any one of the preceding claims, wherein IgG4 in the formulation comprises about 3% to about 70% (wt / wt) of the protein content of the formulation.

17. The method of any one of the preceding claims, wherein IgG4 in the formulation comprises about 0.5% to about 8% (wt / wt) of the protein content of the formulation.

18. A method according to any one of the preceding claims, wherein: (i) IgG1 in the formulation accounts for about 50% to about 70% (wt / wt) of the protein content of the formulation; (ii) IgG2 in the formulation comprises about 27% to about 37% (wt / wt) of the protein content of the formulation; (iii) IgG3 in the formulation comprises about 2.5% to about 8% (wt / wt) of the protein content of the formulation; and (iv) IgG4 in the formulation comprises about 3% to about 70% (wt / wt) of the protein content of the formulation.

19. The method of any one of the preceding claims, wherein the amount of albumin in the formulation is less than about 5 g / L of the formulation.

20. The method of any one of the preceding claims, wherein the Factor XI activity in the formulation is less than about 0.01 E / mL.

21. The method of any one of the preceding claims, wherein the amount of alpha-2-macroglobulin present in the formulation is less than about 0.2 g / L of the formulation.

22. The method of any one of the preceding claims, wherein the amount of transferrin present in the formulation is less than about 0.09 g / L of the formulation.

23. The method of any one of the preceding claims, wherein the preparation has a PL1 activity of less than about 10 nm / mLmin.

24. The method of any one of the preceding claims, wherein the amount of fibrinogen present in the formulation is less than about 35 μg / mL of the formulation.

25. A method according to any one of the preceding claims, wherein the IgG-containing starting material is a frozen supernatant.

26. The method according to any of the preceding claims, wherein members selected from the group consisting of the first chromatography medium comprising a first solid support having Protein A, the first affinity ligand chromatography medium comprising a second solid support bound to a first affinity ligand having IgG binding affinity, and combinations thereof are contained in a single column.

27. The method of claim 26, wherein two or more of the columns are in fluid communication within an array, and wherein two or more of the columns comprise a second chromatographic medium and a second affinity ligand chromatographic medium.

28. The method of claim 27, wherein the outlet of the first column is in fluid communication with the inlet of the second column.

29. The method of claim 28, wherein the outlet of the column having Protein A is in fluid communication with the inlet of the first affinity ligand chromatography medium.

30. The method of claim 27, wherein an outlet of the column containing the second chromatographic medium is in fluid communication with an inlet of the column containing the second affinity ligand chromatographic medium.

31. The method according to any one of the preceding claims, wherein the IgG solution lacking Protein A binding to IgG subclasses comprises a member selected from the group consisting of IgGl, IgG2, IgG3, IgG4, and combinations thereof.

32. A method according to any preceding claim, wherein the first chromatographic medium has a selective affinity for the CH1 domain of human IgG antibodies.

33. A method according to any preceding claim, wherein the first chromatographic medium has a selective affinity for the CH1 domain of a member selected from IgG1 and IgG3 that is greater than the selective affinity for the CH1 domain of a member selected from IgG2 and IgG4.

34. A method according to any one of the preceding claims, wherein elution from the first chromatography medium, the first affinity ligand chromatography medium, and the second affinity ligand chromatography medium uses an eluent comprising glycine.

35. The method of claim 34, wherein the glycine concentration is about 50 mM to about 150 mM.

36. An affinity chromatography method for preparing an IgG preparation enriched in a first IgG subclass having low Protein A binding affinity from a plasma-derived IgG solution lacking Protein A binding IgG subclasses, the method comprising: (a) contacting the IgG solution lacking Protein A binding IgG subclasses with a first affinity ligand chromatography medium, the first affinity ligand chromatography medium comprising a first solid support having a first affinity ligand having IgG binding affinity bound thereto, thereby forming a first bound fraction having low Protein A binding affinity for the first IgG subclass and a first flow-through; and (b) eluting the first bound fraction of the first IgG subclass with low Protein A binding affinity, thereby forming a first eluate comprising the IgG preparation enriched in the first IgG subclass with low Protein A binding.

37. The method of claim 36, further comprising: (c) prior to (b), contacting the first bound fraction of the first IgG subclass with low Protein A binding affinity with a buffer / detergent solution and subsequently removing the detergent solution from the first affinity ligand chromatography medium.

38. The method of claim 36, further comprising: (d) after (b), contacting the first eluate with a second chromatographic medium comprising a solid support having an affinity ligand bound thereto, the affinity ligand having affinity for a second IgG subclass having low Protein A binding affinity, thereby forming a first bound fraction for the second IgG subclass having low Protein A binding affinity; and (e) eluting the first bound fraction of the second IgG subclass having low Protein A binding affinity from the second chromatographic medium, thereby forming a second eluate.

39. The method of claim 38, further comprising: (f) prior to (e), contacting the first bound fraction of the second IgG subclass with low Protein A binding affinity with a buffer / detergent solution and subsequently removing the detergent solution from the first chromatography medium.

40. The method of claim 36, further comprising: (g) prior to (a), contacting the plasma-derived IgG solution with a protein A chromatography medium comprising protein A bound to a solid support, thereby forming a protein A-bound fraction of IgG subclasses having a high affinity for protein A, and the IgG preparation enriched in a first IgG subclass having a low protein A binding affinity.

41. The method of claim 36, further comprising: (h) eluting the Protein A bound fraction of IgG subclass having high affinity for Protein A from the Protein A chromatography medium, thereby forming a third eluate.

42. The method of any one of claims 36-41, further comprising the step of combining two or more of the first eluate, the second eluate, and the third eluate.

43. An aqueous IgG solution comprising at least about 99.5% IgG and less than about 0.5% impurities, wherein the aqueous IgG solution comprises less than about 0.0025E / mg total IgG, preferably less than about 0.0020E / mg total IgG, more preferably less than about 0.0015E / mg total IgG, and most preferably less than about 0.0012E / mg total IgG of active Factor XI as an impurity.

44. An IgG aqueous solution comprising at least about 99.5% IgG and less than about 0.5% impurities, wherein the IgG aqueous solution comprises complement C3 as an impurity at a level of less than about 3.5 μg / mg total IgG, preferably less than about 3.0 μg / mg total IgG, more preferably less than about 2.5 μg / mg total IgG, and most preferably less than about 2.2 μg / mg total IgG.